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ABSTRACT 
Introduction: The oral cavity is the port of entry to the digestive tract. Foods enter the oral 
cavity and mix with saliva, before they are being swallowed and transferred to the more 
downstream regions of the digestive tract. Some foods are not well tolerated, for instance, 
gluten proteins in individuals suffering from celiac disease (CD). Celiac disease (CD) is 
characterized by a chronic immune-mediated inflammation of the duodenum, triggered by 
gliadin component of gluten contained in wheat, barley and rye. In previous studies we 
showed that oral Rothia bacteria can degrade gluten in vitro. The functions of oral bacteria, 
such as Rothia bacteria, beyond the oral cavity are largely elusive, despite the fact that 
large volumes of saliva, containing billions of bacteria including Rothia bacteria, are being 
swallowed on a daily basis. The role of oral bacteria in the digestion of foods is virtually 
unexplored. 
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The overall objective of this study was to gain more insights into the role of Rothia bacteria 
and subtilisin enzymes on gluten digestion in vivo, with the ultimate goal to find new 
therapeutic options for CD patients. Specifically, the objectives of this study were 1) To 
isolate and identify the enzyme from Rothia aeria, and to assess if the oral R. aeria bacteria 
can contribute to the digestion of gluten proteins in vivo; 2) To assess the properties, 
stability and characteristics of the subtilisin-A enzyme; and 3) To protect and maintain 
subtilisin-A enzyme activity by exploring two pharmaceutical modification techniques: 
PEGylation and Polylactic glycolic acid (PLGA) microencapsulation. Materials and 
Methods: The corresponding materials and methods consist of three parts. Part I: Rothia 
bacterial proteins were separated by SDS page and analyzed for enzyme activity by 
zymography, and the band with activity was excised and subjected to LC-ESI-MS/MS 
analysis. For in vivo activity assessment of Rothia bacteria, mice chow was prepared with 
and without admixed R. aeria bacteria (OD620nm 200 per 1 g of chow). Mice (n=9/group) 
were fed with the various chow, euthanized and gliadin degradation and epitope 
abolishment was assessed in the stomach contents by gel electrophoresis and in an ELISA 
assay with the monoclonal antibody R5, which recognizes highly immunogenic gluten 
epitopes. Part II: Subtilisin-A (1 mg/ml) was dissolved in various solutions including 
deionized water, 50% DMSO, sodium carbonate buffer (pH 10), 31 mM HCl (pH 1.5) or 
PMSF (1 µg/ml), and incubated on ice for 1 h. The effect of exposure to various 
temperatures from 0°C to 100°C, and incubation time from 0h to 72h on enzyme activity 
were also assessed. Protein stability was analyzed by SDS-PAGE. The enzyme activity 
was determined by using a para-nitroanilide-derivatized substrate (Suc-AAPF-pNA) and 
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by casein zymography. Part III: PEGylation of subtilisin-A (Sub-A) was performed by 
mixing Sub-A with methoxypolyethylene glycol (mPEG, 5 kDa) in borate buffer (pH 9.0). 
After stirring at 4°C, the mixture was quenched with potassium phosphate buffer (pH 6.9), 
dialyzed to remove unbound mPEG and lyophilized. The extent of mPEG modification 
was assessed. The PEGylated Sub-A (mPEG-Sub-A) was further encapsulated by 
polylactic glycolic acid (PLGA). The activity of the modified enzyme was evaluated at pH 
3.0 using the substrate Suc-AAPF-pNA. The efficacy of detoxifying immunogenic gliadin 
epitopes was assessed using an R5 monoclonal antibody-based ELISA. Results: Part I: 
The R. aeria gliadin-degrading enzyme was found to be a member of the subtilisin family, 
and is encoded by BAV86562.1, and is mislabeled as an ABC transporter in NCBI. The R. 
aeria enzyme is substantially different from the previously isolated R. mucilaginosa 
enzymes (WP_044143864.1 and WP_ WP_044143865.1). In vivo, fasted mice readily 
consumed the 1 g chow without or with the added R. aeria bacteria. Gliadins were reduced 
by 20% and its immunogenic epitopes were reduced by 32.6 % as compared to mice 
receiving chow without Rothia bacteria. Part II: Sub-A dissolved at pH 1.5 showed a band 
of 27 kDa, while it only showed low molecular weight bands (<10 kDa) when dissolved at 
pH 7.0 or pH 10, suggesting auto-proteolysis at neutral and basic pH conditions. The 
activity of the enzyme remained high in 50% DMSO, but was inhibited in the presence of 
PMSF and at pH 1.5. The enzyme activity decreased at incubation temperatures increasing 
from 37°C to 100°C, and the activity was completely lost at temperatures exceeding 60°C. 
Activity loss due to autolysis was more than 4 fold after 6 h incubation at 37°C at neutral 
pH conditions. Prolonged incubation time led to the disappearance of the low MW bands 
x 
in SDS-PAGE due to continued proteolysis, and significantly reduced cleavage activity 
towards Suc-AAPF-pNA. Part III:  The extent of mPEG modification achieved was 55% 
(~6 of 10 primary amines in Sub-A were PEGylated). The PEGylation protected subtilisin-
A from autolysis. The microencapsulated Sub-A-mPEG-PLGA showed significantly 
increased protection against acid exposure in vitro. In vivo, gluten immunogenic epitopes 
were decreased by 60% in the stomach of the mice fed with chow containing Sub-A-
mPEG-PLGA (0.2mg Sub-A/ g chow) (n=9) compared to 31.9 % in mice fed with 
unmodified Sub-A (n=9). Conclusion: The part I results provide proof of concept for the 
potential in vivo contribution of oral Rothia bacteria to gluten digestion. The part II results 
show that Sub-A undergoes significant autolysis, a feature that can potentially be 
circumvented by pharmaceutical modification. The part III results show that 
pharmaceutical modification can protect Sub-A from auto-digestion as well as from acidic 
insults, thus rendering the enzyme more suitable for applications in vivo. While the 
formulation and doses would need to be further optimized to achieve reduction of gluten 
levels to <20 ppm, the required safety level for CD patients, the usefulness of coated 
subtilisins as a digestive aid for gluten degradation was demonstrated. 
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1. INTRODUCTION 
1.1. Features of the human digestive tract 
The human digestive system consists of the gastrointestinal tract and the accessory organs 
needed for food processing and digestion. These comprise the dentition, tongue, salivary 
glands, stomach, pancreas, liver, and gallbladder (Moore and Agur 2002). In this system, 
the process of digestion is carried out, starting with the mixing of foods with human saliva, 
and the formation of a food bolus, which is then swallowed to reach the esophagus and 
then the stomach (Jalabert-Malbos et al., 2007). In the stomach the contents are mixed with 
gastric acid until it passes to the duodenum as a chyme, where it is neutralized and mixed 
with a number of enzymes produced by the pancreas. The oral cavity, stomach and 
duodenum therefore each contribute differently to the digestive process. The role of the 
oral cavity and its contents in the digestion of foods is relatively unexplored. 
 
1.1.1. The oral cavity 
The oral cavity represents the entrance to the digestive tract that all ingested food has to 
pass. Foods are mixed with saliva, which contains a large variety of epithelial and microbial 
cells, and the exocrine components produced by the salivary glands. Saliva functions 
initially in the digestive system to moisten and soften food to form a food bolus (Edgar 
1992). Bolus formation is further helped by the lubrication provided by the major mucous 
glycoproteins in saliva, MUC5B and MUC7.  
The most studied role of saliva though has been in relation to the maintenance of 
the oral hard and soft tissues. Saliva maintains the pH of the mouth at around pH 6.7 (Baliga 
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et al., 2013). Saliva is supersaturated with respect to calcium and phosphate ions. Statherin 
and acidic proline-rich salivary proteins prevent the precipitation of these ions in saliva. 
Rendering saliva supersaturated with respect to calcium and phosphate salts help in the 
remineralization of parts of the enamel that were transiently demineralized due to exposure 
to acids, e.g. those in acidic beverages or, lactic acid produced by cariogenic bacteria. 
Further, saliva acts as a buffer by virtue of containing bicarbonate and phosphate ions, 
keeping the acidity of saliva within a certain range, typically pH 6.2–7.0. Enamel 
homeostasis ensures that the dentition, needed for chewing of foods, remains intact over a 
lifetime.  
With regard to digestion, saliva is known to contain the digestive enzymes amylase 
and lipase. Amylase degrades starch into maltose and dextrose, which can be further broken 
down in the small intestine. Lipase is involved in the digestion of fats. Proteolytic activities 
in saliva have been known for quite some time (Soder 1972). However, specific studies on 
digestion of individual dietary proteins, such as gluten proteins, are sparse (Tian et al., 
2014).   
 
1.1.2. The stomach 
The stomach is a major organ of the gastrointestinal tract and digestive system. It is a J-
shaped organ joined to the esophagus at its upper end and to the duodenum at its lower end. 
Hydrochloric acid produced by gastric chief cells in the stomach play a vital role in the 
digestive process. In the fasting state the pH of gastric fluid is in the 1.3 to 2.5 range. Eating 
can increase the pH to a 4.5 to 5.8. Within 1 h after eating, the pH of the stomach decreases 
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again to less than 3.1 (Dressman 1986; Malagelada et al., 1976). Pepsinogen is a precursor 
enzyme produced by the gastric chief cells. Gastric acid activates pepsinogen to generate 
the enzyme pepsin which then begins the digestion of proteins. Gastric juice contains 0.8 
to 1 mg/mL pepsin (Dean and Ma 2007; Vertzoni et al., 2005). 
 
1.1.3. The duodenum 
The most upper part of the small intestine is called the duodenum. Food arrives in the 
duodenum in the form of an acidic chyme. The pH becomes crucial; since it needs to be in 
the neutral range in order to activate digestive enzymes that have a more neutral optimum 
pH. This is achieved in the duodenum by the addition of bile from the gallbladder combined 
with bicarbonate ions secreted from the pancreatic duct and bicarbonate-rich mucus 
secreted from the duodenal glands known as Brunner's glands (Moore and Agur 2002). The 
resulting alkaline fluid mix neutralizes the gastric acid which would otherwise damage the 
lining of the intestine.  
When the digested food particles are reduced enough in size and composition, they 
can be absorbed by the intestinal wall and carried to the bloodstream (Hall 2011). The first 
container for this chyme is the duodenal bulb. From here it passes into the first of the three 
sections of the small intestine, the duodenum. The next section is the jejunum and the third 
is the ileum. The duodenum is the first and shortest section of the small intestine. It is a 
hollow, jointed C-shaped tube connecting the stomach to the jejunum. It starts at the 
duodenal bulb and ends at the suspensory muscle of the duodenum (Jit and Grewal 1977).  
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Most food digestion takes place in the small intestine. Contractions act to mix and 
move the chyme more slowly in the small intestine allowing more time for absorption. In 
the duodenum, pancreatic lipase is secreted to further digest the fat content of the chyme 
(Kong and Singh 2008). Also, the pancreas secretes chymotrypsinogen and trypsinogen. 
Trypsinogen gets activated and converts to trypsin by an endopeptidase enzyme produced 
by digestive cells lining the intestines called enterocytes. Subsequently, chymotrypsin gets 
activated by trypsin. Enterocytes are unusual cells in that they have villi on their surface 
which in turn have innumerable microvilli on their surface. All these villi make for a greater 
surface area, facilitating not only the absorption of the chyme but also the further digestion 
by large numbers of digestive enzymes present on the microvilli. 
 
1.2. Diseases of the digestive tract 
Each part of the digestive system is subject to a wide range of disorders. Stomach diseases 
are often chronic in nature and include gastroparesis, gastritis, and peptic ulcers (Vaisman 
et al., 2006). Also, a number of problems including malnutrition and anemia can arise from 
malabsorption, the abnormal absorption of nutrients in the GI tract (Pera et al., 2002). 
Malabsorption can have many causes ranging from infection, to enzyme deficiencies. It 
can also arise from inflammation in combination with a specific food trigger, such as in 
celiac disease (CD). CD is a chronic inflammatory immune-mediated disease affecting the 
duodenum (Schuppan et al., 2009). The inflammation can cause vitamin deficiencies due 
to the improper absorption of nutrients in the small intestine.  
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1.3. Celiac disease: epidemiology, cause, symptoms, and modality of treatment 
Gluten is found in wheat, barley and rye and triggers CD, a chronic inflammatory immune-
mediated disease affecting the duodenum (Schuppan et al., 2009). Globally CD affects 
between 1 in 100 people (Fasano and Catassi 2012). CD may develop at any age, and it’s 
more common in women than in men, showing a ratio of 3:1 (Ciacci et al., 1995; 
Ciccocioppo et al., 2015).  Immunogenic gluten proteins show unusual resistance to 
degradation by human digestive enzymes (Gass and Khosla 2007; Helmerhorst et al., 
2010). Surviving gluten-derived peptides reach the lamina propria in the duodenum where 
they are deamidated by the enzyme tissue transglutaminase (Dieterich et al., 1997). 
Toxicity is peptide length-dependent where peptides shorter than 8 residues are less able 
to generate an immunogenic response. Therefore, detoxification of gluten can theoretically 
be achieved by their proteolytic fragmentation.  
Gliadins and glutenins are the two main components of gluten (Green and Jabri 
2006). Glutens are abundantly present in everyday diet of most individuals, except of 
people suffering from CD who carefully avoid the ingestion of these proteins. Gluten are 
proline (P) and glutamine (Q) rich proteins, and due to repetitive PQ sequences they are 
difficult to be degraded by mammalian digestive tract enzymes (Papista et al., 2012; Wieser 
1995). The strongest and most common adaptive immune response to gliadin is directed 
toward a α2-gliadin fragment of 33 amino acids in length 
(LQLQPFPQPQLPYPQPQLPYPQ-PQLPYPQPQPF) (Van Heel and West 2006). 
Clinical manifestations of CD are intestinal cramps, chronic diarrhea, and when 
unaddressed, CD can lead to villous atrophy, malabsorption of nutrients, minerals, and fat-
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soluble vitamins A, D, E, and K, and small stature in children (Volta et al., 2014). If CD is 
left untreated, it may result in cancers such as intestinal lymphoma and a slight increased 
risk of early death (Lebwohl et al., 2015). 
The gliadin peptides that resist proteolytic degradation by trypsin, chymotrypsin, 
and other mammalian digestive enzymes interact with enterocytes, reducing tight junctions 
and facilitating gliadin transport to the lamina propria (Barone et al., 2016). There, they 
interact with tissue transglutaminase (tTG) (Dieterich et al., 1997; Lammers et al., 2008), 
an enzyme which converts selected glutamine residues to glutamic acid. The deamidated 
peptides represent antigens which react with HLA-DQ2 or HLA-DQ8 histocompatibility 
complex. This is part of the MHC class II antigen-presenting receptor (also called the 
human leukocyte antigen) system, eliciting an inflammatory immune response. The 
cascade of events is summarized in Figure 1. 
Therapeutic modalities for CD include either dietary or non-dietary approaches. 
Dietary therapy comprises a lifelong strict elimination of gluten from the diet. The 
decreased tastiness of gluten-free products, however, and the abundant presence of gluten 
in the diet make it difficult to maintain a gluten-free diet. Further, the gluten-free diet poses 
a significant social and financial burden to the patient (Welstead 2015). Furthermore, up to 
30% of patients continue to have gastrointestinal symptoms despite self-reported adherence 
to a strict gluten free diet (See et al., 2015). In the United States, the FDA issued regulations 
in 2013 limiting the use of "gluten-free" labels for food products to those with less than 20 
ppm of gluten. The current international Codex Alimentarius standard allows for 20 ppm 
of gluten in so-called "gluten-free" foods. Even on a strict gluten-free diet, it is often 
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impossible to avoid traces of gluten that can cause symptoms of the disease (See et al., 
2015).  
Non-dietary therapy consists of three strategies, targeting individual steps in the 
gluten toxicity cascade: gluten (gliadin) degradation and detoxification; modulation of 
intestinal permeability; and modulation of the immune response.  
A questionnaire survey has been conducted to investigate which of the various 
therapeutic approaches was most appealing to CD patients (Branchi et al., 2016). It 
revealed that 65% of CD patients want an alternative therapy to the gluten free diet, and 
they preferred the use of gluten degradation and detoxification medications over other, 
generally more risky, non-dietary therapies to treat CD. 
 
Figure 1. Schematic illustration of the gliadin enteropathy mechanism characteristic 
for CD. Adopted from Charles Williams, 2011 
  
8 
 
1.4. Gliadin-degrading strategies 
1.4.1. Microbes: Rothia aeria bacteria 
The oral cavity is the port of entry through which food contents mixed with saliva reach 
the rest of the gastrointestinal tract. The oral cavity is colonized with over 700 different 
microbial species or phylotypes (Dewhirst et al., 2010; Fernandez-Feo et al., 2013). Saliva 
harbors over 100 million bacterial cells per milliliter. In fact, the oral cavity is, after the 
colon and the cecum, the most densely populated part of the human gastrointestinal tract 
(Stearns et al., 2011). The various parts of the GI tract each harbor their individual 
microbial communities, forming an oral microbiome, a gut microbiome, gastric 
microbiome, each with distinct compositions (Hillman et al., 2017). The functions and 
properties of many single species within these mixed culture microbiomes remain 
unknown. Furthermore, the potential roles of e.g. oral species to physiological processes 
in other parts of the digestive canal is virtually unknown. Oral Rothia bacteria were recently 
shown to produce enzymes that degrade dietary gluten proteins in vitro (Helmerhorst et al., 
2010) (Zamakhchari et al., 2011). This points to potentially novel functions for oral 
microorganisms in digestion, reaching beyond the oral cavity. 
The Rothia genus, formerly called Stomatococcus, comprises several species, 
including R. aeria, R. mucilaginosa and R. dentocariosa. They are gram-positive microbes 
that thrive well in the oral environment. R. mucilaginosa has been detected at low levels in 
the duodenum as well (Ou et al., 2009). Little is known on the functional role that these 
species play in the oral cavity, other than that they are mostly associated with oral health 
(Ramanan et al., 2014). Thus, it was of interest when the gluten-degrading capabilities of 
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the Rothia bacteria were discovered, specifically for the Rothia mucilaginosa and Rothia 
aeria species (Tian et al., 2014; Wei et al., 2016; Zamakhchari et al., 2011), which may 
suggest a role of these bacteria in protein degradation.  
The gluten-degrading activities of oral bacteria were discovered with a selective 
gluten agar cultivation approach, and enzyme activities towards gluten were verified in 
enzymatic assays using a variety of gluten-derived enzyme substrates (Helmerhorst and 
Wei, 2009). The gluten-degrading enzymes produced by the Rothia mucilaginosa were 
identified as two structurally closely related subtilisins (Wei et al., 2016). One of the two 
subtilisins was 1328 amino acids in length, comprised an signal peptide of 38 amino acids, 
a propeptide domain of 120 amino acids, three repeats of predicted surface layer homology 
(SLH) domains, and a peptidase S8/S53 domain at the N-terminal region of the protein. 
The catalytic domains spans residues 174 to 617 and comprises the typical D-H-S catalytic 
triad of the subtilisin family of proteases (Wei et al., 2016). 
 
1.4.2. Enzymes - Subtilisin enzyme: Structure, Function 
Digestion of gluten immunogenic epitopes is one of the strategies that is being explored 
for the treatment of CD (Kurada et al., 2016). Initial studies in this area were carried out in 
the late 1950s utilizing nonhuman enzymes (Krainick and Mohn 1959). It has been reported 
(Krainick et al., 1959), that after wheat gluten has been digested by crude papain (a 
commercial product prepared from the latex of the unripe papaya) it is no longer harmful 
when ingested by CD patients. This phenomenon has not been investigated further, and it 
is not known whether the 'detoxification' is caused by papain itself or by another enzyme 
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contained in the crude product, such as chymopapain (Jansenand Balls, 1941) or an enzyme 
acting on peptides. This enzyme was not further explored for reasons of eliciting 
hypersensitivity (Mansfield et al., 1985). The concern of hypersensitivity would 
conceivably be less if the source of the enzyme is from bacteria naturally associated with 
the human body.   
A promising new source of gluten-degrading enzymes are the microbes that 
colonize the human digestive canal, starting in the oral cavity (Caminero et al., 2014). 
Rothia mucilaginosa as well as Rothia aeria, two natural colonizers of the oral cavity, exert 
a high gluten-degrading activity at pH 7.0. Both are capable to cleave (↓) gluten after QPQ↓ 
and LPY↓, sequences which are abundant in immunogenic gliadin domains. The enzymes 
from Rothia mucilaginosa have been isolated in our laboratory and were identified as 
subtilisins (Wei et al., 2016). The subtilisin enzymes, many being food-grade such as the 
ones from Bacillus species, could potentially benefit CD patients if they could abolish 
gliadin epitopes during gastro-duodenal transit in vivo. In vitro, the Bacillus and Rothia 
enzymes both effectively degrade gliadin immunogenic epitopes implicated in CD (Wei et 
al., 2016).  
There are a few oral enzymes currently being explored to treat CD, some of which 
have reached clinical trials. Two enzymes, prolyl endopeptidase from Sphyngomonas 
capsulata and a glutamine-specific cysteine endopeptidase (EP-B2) from barley, together 
present in the drug ALV003 (Alive Pharmaceuticals), have been profoundly investigated 
for their effect on gluten detoxification (Cornell et al., 2005; Gass and Khosla 2007; Marti 
et al., 2005; Mitea et al., 2008; Stepniak et al., 2006; Van Heel and West 2006). However, 
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neither of these enzymes are naturally associated with the human body. A preliminary 
clinical study showed that the effectiveness of endopeptidase (PEP) from  F. 
meningosepticum is restricted to the length of suitable substrate (Shan et al., 2004), and 
that they were optimally active at neutral pH. (Cerf-Bensussan et al., 2007). Another prolyl 
endopeptidase currently being explored is called Tolerase G from Aspergillus niger (AN-
PEP). It is more active at low pH, but requires more clinical experiments and investigation 
since the clinical endpoints were not met due to lack of clinical deterioration in the placebo 
group (Stepniak et al., 2006; Tack et al., 2013).  
Subtilisins are a group of serine proteases. The subtilisin enzymes from Rothia 
bacteria are quite different than the ones from Bacillus species, from which they were 
originally isolated. The subtilisins from the Bacillus species typically range in MW from 
26 to 28 kDa. The subtilisins from Rothia however, are much larger in size. The identified 
subtilisins  from Rothia mucilaginosa for instance, were 140 kDa in size in the prepro 
enzyme form and approximately 70-75 kDa in their active form, as estimated by gel 
electrophoresis (Zamakhchari et al., 2011). Bacillus subtilisins have an isoelectric point of 
9.4 (Wong 1995). They are secreted in large quantities by many Bacillus species. The first 
subtilisin enzyme was discovered by Linderstrom-Land and Ottesen (Linderstrom-Land 
and Ottesen 1947) and purified by Gtintelberg and Ottesen (Ottesen and Spector 1960), 
and was called subtilisin Carlsberg. This enzyme has also been called subtilisin-A (Sub-
A).  
Sub-A is produced by Bacillus licheniformis (Keay and moser 1969). Sub-A 
contains a 76-residue pro-peptide region in addition to the 274 amino acids. The pro-
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sequence is cleaved from the mature protein through auto-proteolysis to produce the active 
mature Sub-A of 27 kDa. Sub-A forms a single polypeptide chain (Jacobs et al., 1985). 
The secondary structure comprises two alpha-helices and a large beta-sheet structure 
(colored in blue and yellow, respectively, in Figure 2). Like other serine proteases, the 
subtilisin catalytic triad is composed of Asp (D), His (H) and Ser (S), in Sub-A, Asp is at 
position 32, His at position 64, and Ser at position 221. The enzyme also contains Asn (N) 
at position 155 which assists the catalytic triad in the attack of the peptide bond by a 
neighboring carboxyamide side-chain as shown in Figure 2. Given their food-grade status, 
subtilisins have a clear potential to be used as digestive aides for gluten degradation. 
However, the challenge for such an application is the reduced activity of subtilisins under 
acidic conditions, a challenge it shares e.g. with the bacterial prolyl endopeptidases. 
Furthermore, an additional challenge, which became apparent during the course of this 
work, was that Sub-A under neutral conditions is unstable and undergoes substantial 
autolysis. 
With the advances in biotechnology and chemistry, therapeutic potency of proteins, 
e.g. enzymes, can be improved through the application of pharmaceutical modification 
with enteric coating techniques. The modifications include PEGylation and 
microencapsulation.  
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Figure 2.  Schematic of the subtilisin-A structure and sequence. The structure was 
adopted from Brandoon and Tooze, 1998; the sequence was taken from the MEROPS 
database, where the first sequence shows the propeptide, and the second shows the active 
enzyme, and the red underlined residues represent the catalytic triad amino acids. 
 
1.5. Enteric coating and drug delivery 
An enteric coating is a polymer barrier applied to an oral medication such that it prevents 
its disintegration in the gastric environment (Peter 1990). The enteric coating allows the 
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release of the drug in a targeted area of the intestinal tract. Enteric coating protects drugs 
such as therapeutic proteins, from acidity and/or from proteases operating in the stomach 
(Bundgaard et al., 1982). Enteric coating is also a beneficial means to deliver a drug without 
loss of effective concentration in a specific targeting part of the digestive tract. 
 
1.5.1. Techniques of enteric coating 
Enteric coating can be achieved with by various techniques e.g. PEGylation, 
microencapsulation, surface spray, crystallization which will be discussed below. They 
have been used individually, or sequentially, and in various combinations to achieve the 
desired protective properties. 
The first technique to be discussed is PEGylation. The PEGylation technique was 
first described by Abuchowsky et al. in 1977 on modifications of catalase and albumin 
(Abuchowski et al., 1977). The PEGylation technique consists of covalent and non-
covalent attachment of Poly ethylene glycol (PEG) to a molecule such as a therapeutic 
protein. thereby enhancing its protection from proteolytic degradation and increasing its 
stability (Vinogradov et al., 1999). PEG reagents have -OH functional group attached to 
the PEG polymer, which  react with the N-terminal amine group and with the ɛ-amine 
group in lysine residues to form an amide bond after activation of the PEG functional group 
with cyanuric chloride as shown in Figure 3A (Jevševar et al., 2010). Lysines are relatively 
abundant amino acid residues frequently located on the protein surface, which make them 
prone to chemical reactions with PEG reagents. Reactions advance quickly and lead to 
complex mixtures of conjugates, differing in the number and site of the attached PEG 
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chains (Turecek et al., 2016). PEGylated proteins can be further modified by another 
enteric coating technique, e.g. microencapsulation, to achieve further protection in the 
digestive canal.  
2- Microencapsulation is a technique of enteric coating to form microparticles. 
Microparticles made of albumin as a drug delivery system were first reported by Kramer 
in 1974 (Kramer 1974). More than 20 years later, the use of microencapsules as sustained 
release vehicles through the pores of the microencapsule was proposed by Java Krishna & 
Catha, as cited in (Madhav and Kala 2011). Some investigations using hemoglobin instead 
of albumin as natural biodegradable carriers for drugs for microparticle administration have 
also been performed (Brookes et al., 2006).  In our study we used poly (lactic-co-glycolic 
acid) (PLGA) copolymers (Figure 3B). 
3- Surface coating by layer by layer or spray drying. Sequential layer by layer 
coating was introduced in 1998 by Decher and coworkers (Decher et al., 1998). It results 
in polymeric structures that consist of two opposite charges of organic polyelectrolytes that 
are held together by electrostatic forces. The assembly requires a core or template onto 
which the layer by layer construction can be built. The ultimate size of the microparticle 
will depend on the core size (Johnston et al., 2006). Spray drying is a method used to protect 
sensitive substances from oxidation and is achieved by the atomization of a solution by 
compressed air and drying across a current of warm air (Jalil and Nixon 1992). 
4- Crystallization is the result of crosslinking of proteins in the crystalline state. It 
is initiated by a nucleation step when the protein becomes super-saturated and form nuclei, 
followed by protein precipitation on the surface in layers. This step is called crystal growth. 
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The protein crosslink via non-covalent attachments, e.g. dipole-dipole interactions “van 
der Waals” forces, hydrogen bonds, hydrophobic interactions, and ionic bond (Rhodes 
2006). Crystallization provides more stability to the protein, and maintains protein 
conformation and structure (Madan et al., 1976; Margolin and Navia 2001). It has a few 
drawbacks which are technique sensitive, such as the prolonged time to get the crystal 
product, and the low amounts of crystals formed.  
 
Figure 3. Chemical reaction of the activated mPEG with amine group (A) and 
methoxy polyethylene glycol with poly lactic glycolic acid (mPEG-PLGA) (B). 
 
A 
B 
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1.5.2. Microparticles 
Microparticles are defined by the International Union of Pure and Applied Chemistry 
(IUPAC) as particles with sizes ranging from 0.1 to 100 μm (IUPAC 2002). The 
microparticles are subdivided into two different categories:  microcapsules or microspheres 
(Figure 4): In polymer microcapsules the drug forms a core which is surrounded by an 
outer layer of polymer, whereas in microspheres the drug is homogenously distributed in 
the particle (Spiegelberg 2004). 
 
Figure 4. Dispersity of drugs in different microparticles a) In microcapsules the drug 
is forming a core (in black) surrounded by a polymer layer (in gray); b) In microspheres 
the drug is homogenously dispersed throughout the particle (in black). Spiegelberg et al, 
2004. 
 
1.5.3. Microcapsule and microsphere formation by different methods 
There are several methods by which microcapsules and microspheres can be formed, e.g. 
emulsion, phase separation, interfacial polymerization which are summarized below. 
1. Emulsion–solvent evaporation or extraction (oil in water “o/w”, water in oil 
“w/o”, water in oil in water “w/o/w”) as shown in Figure 5. The Emulsion–solvent 
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evaporation or extraction technique is the most common procedure used for microcapsules 
and microspheres formation. For a single emulsion (o/w, w/o) or double emulsion (w/o/w), 
the solvent evaporation method such as water in oil (w/o) involves the emulsification of an 
organic solvent containing dissolved polymer, and dissolved protein in an excess amount 
of aqueous continuous phase, with the aid of agitation, homogenization or sonication. The 
concentration of the emulsifier present in the aqueous phase affects the particle size and 
shape. If the desired emulsion droplet size is produced, the stirring rate is reduced and 
organic solvent evaporated under atmospheric pressure at an appropriate temperature. 
Subsequent evaporation of the solvent make the solid polymeric microparticles entrapping 
the drug (Thies 1987). In the solvent extraction process, the emulsion is transferred to water 
to extract the organic solvent, and then the solid microparticles are retrieved from the 
suspension by filtration or lyophilization. The microparticles will be more porous when the 
solvent extraction process is used than when the solvent evaporation process is used (Yeo 
et al., 2001).  
2. Phase separation (non-solvent addition and solvent partitioning): In this process, 
both the drug and the polymer should be insoluble in water, while a water-immiscible 
solvent such as acetonitrile is required for the polymer. This technique can be done by 
temperature change, non-solvent or salt addition, incompatible polymer addition, and 
polymer–polymer interaction (Figure 6) (Kas and Oner 2000).  
3. Interfacial polymerization: in this technique, two monomers, one oil-soluble and 
the other water-soluble, are employed and a polymer is formed on the droplet surface. The 
method involves the reaction of monomeric units located at the interface existing between 
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a core material substance and a continuous phase in which the core material is dispersed. 
An example of this method is the production of nylon microcapsules (Figure 7) (Whateley 
1996). 
 
Figure 5. Microencapsulation emulsion methods for the delivery of protein drugs. 
From: Yoon Yeo et al., Biotechnol. Bioprocess Eng. 2001. 
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Figure 6. Diagram of microencapsulation by the phase separation method. From: 
Burgess et al, 1994 
 
 
Figure 7. Microencapsulation by the interfacial polymerization method. From: 
Whateley, et al., 1996. 
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1.5.4. Polymer materials used for enteric coating 
A wide variety of different polymer materials are used nowadays. In our study we 
employed two polymers that will be discussed below. Polymers have been explored for the 
effective oral delivery of therapeutic agents, including proteins, nucleic acids, and 
insoluble drugs (Li et al., 2013). 
The polymers serve to solubilize, to stabilize and to enhance drug, or enzyme 
properties. They can be classified based on source, structure, type of polymerization, 
molecular forces and degradability. 
 
A) Hydrophilic polymers 
Natural or synthetic hydrophilic polymers are large molecules that are soluble or 
dispersible in aqueous solutions. A capsule wall made of hydrophilic polymers presents a 
good barrier to oily and hydrophobic materials, but it is usually a poor barrier to hydrophilic 
substances. Examples are agar, acrylic polymers, poly acryl methacrylate, gelatin, waxes 
(poly hydroxyl butyrate-co-valerate), cellulose derivatives, and poly ethylene glycol 
(PEG). 
PEG is a polyether diol which is amphiphilic, highly soluble and not charged in 
solution which make it suitable for biological applications. Currently, two different types 
of PEG are available, the linear and the branched form. At molecular weights below 1 kDa, 
PEG is in a viscous liquid. At molecular weights above 1 kDa, PEG becomes a solid. PEG 
is approved by the European Medicines Agency (EMA) and the Food and Drug 
Administration (FDA) for human administration by mouth, injection or dermal application. 
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It is inert, non-toxic and non-immunogenic (Harris and Chess 2003). The clearance of the 
body takes place through renal clearance if the polymer is below 30 kDa and otherwise 
through the liver or feces (Chavez et al., 2006). The production of PEG is conducted by 
anionic polymerization. Two OH-groups at both ends of the PEG chain can be activated 
for the purpose of chemical protein modifications (Zalipsky 1995). PEG can enhance the 
physical and chemical stability of drugs and prevent their aggregation in vivo. It has a low 
polydispersity index (PDI) which makes the polymer homogenous and applicable 
pharmaceutically (Kadajji and Betageri 2011). PEG-drug conjugates are being evaluated 
for a variety of molecules and drugs. The main advantages of PEG conjugation is the 
reduction of protein immunogenicity and protein enzymatic degradation. Both help a 
protein drug to reach the site of action and prevent clearance from the body because it is 
not recognized as a foreign body. Moreover, free PEG administered intramuscularly or 
subcutaneously exhibits little to no immunogenicity (Yang and Lai 2015). 
 
B) Hydrophobic polymers 
The most popular synthetic biocompatible polyesters are poly (lactic-co-glycolic acid) 
copolymers (PLGA). PLGA is a water-insoluble polymer. Its strength, hydrophobicity, and 
pliability are its significant physical advantages (Sah et al., 1995). The degradation rate 
and mechanical properties of PLGA can be precisely controlled by varying the ratio of 
lactic and glycolic acids and by alternation of PLGA molecular weights (Park et al., 2005). 
If the polymer is produced with a high ratio of glycolic acid (up to 70 %) it degrades faster. 
The degradation of PLGA is also accelerated with a decreasing molecular weight, because 
23 
 
the higher content of carboxylic groups at the end of the polymer chain increase the acid-
catalyzed degradation (Wischke and Schwendeman 2008). 
As a polymeric vehicle, predictability of degradation, ease of fabrication, and 
regulatory FDA approval are features that make PLGA desirable for medical applications 
(Crotts and Park 1995; Gombotz and Pettit 1995). 
 
1.5.5. Enteric coated dietary enzyme supplements 
The enteric coating technology has been used for protein and enzymes to enhance their 
stability and efficacy. Currently, there are several formulations of digestive enzymes 
supplementation available on the market as non-enteric coated and enteric coated. Among 
them only six oral animal-derived digestive enzymes have obtained FDA approval in the 
United States. They are Creon, Zenpep (2009), Pancreaze (2010), Ultresa, Pertzye (2002), 
and Viokace. All of them are enteric coated except Viokace which is non-enteric coated 
(Ianiro et al., 2016). The enteric coated digestive enzyme formulations contain pancrelipase 
(a mixture of lipase, protease, and amylase) and pharmaceutical excipients e.g. filler 
diluent, binder, disintegrant, lubricant, coloring agent and preservative. Among the FDA-
approved enteric-coated enzyme products, only Creon contains polyethylene glycol (PEG) 
and none of them contain Poly lactic glycolic acid (PLGA) (RxList-Database 2004). It is 
expected that the efficacy of these enzymes, and subtilisin enzymes, can be further 
improved with the application of the appropriate enteric coating technologies, which is 
pursued in this study. 
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2. RATIONALE AND OBJECTIVES  
Food allergies and intolerances are on the rise. Celiac disease is one form of food 
intolerance, and is the most prevalent of all. Strict gluten elimination to date is the only 
therapeutic strategy for CD. The naturally occurring gluten-degrading oral Rothia bacteria, 
and gluten-degrading subtilisin enzymes could offer novel perspectives for the 
development of therapies for CD in the form of probiotics or digestive enzyme supplements 
provided they are active under gastro-duodenal conditions in vivo.  
The objectives of this study were to:  
1) Isolate and identify the enzyme from R. aeria, and to assess if the oral R. aeria 
bacteria can contribute to the digestion of gluten proteins in vivo. 
2) Assess the properties, stability and characteristics of the Sub-A enzyme from B. 
licheniformis (in the absence of quantitative amounts of the Rothia subtilisin enzymes). 
3) Protect and maintain Sub-A enzyme activity under gastro-duodenal conditions 
by exploring the pharmaceutical enteric coating techniques, PEGylation and PGLA 
microencapsulation, and evaluate the activity of modified Sub-A in vivo. 
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3. MATERIALS AND METHODS 
3.1. Part I 
3.1.1. Cultivation of Rothia aeria 
Rothia aeria strain WSA-8 (Zamakhchari et al., 2011) has been deposited as strain HM-
818 to the BEI resources (beiresources.org) and has been sequenced. It is equivalent to R. 
aeria Oral Taxon 188, strain F0474 (HMP ID 1324). To identify the gluten-degrading 
enzyme produced by R. aeria, the bacteria were cultured on Brucella agar plates (Hardy 
Diagnostics, Santa Maria, CA) at 37oC for 48 h under aerobic conditions. The cells were 
harvested from plate with a cotton swab and suspended in sterile PBS to an OD620 5.0. Four 
aliquots of 1.5 ml of the suspension were centrifuged and the supernatants were removed. 
 
3.1.2. SDS-PAGE and casein zymography 
The four cell pellets were re-suspended each in 200 µl zymogram sample buffer 
(Helmerhorst and Wei 2014). To separate the proteins, the samples were applied to a non-
reducing (no DTT or β-mercaptoethanol-containing) 6% SDS-PAGE gel of 16 cm x 20 cm 
x 0.15 cm, using a protean II xi cell system (Bio-Rad, Hercules, CA). The composition of 
this gel was the same as that of previously published 6% gliadin zymogram gels but without 
incorporation of gliadin (Helmerhorst and Wei 2014).  After electrophoresis at a constant 
voltage of 120V at 4°C, the gel was divided in two halves (Figure 8). The first half was 
stained with 0.1% Coomassie Brilliant Blue in 40% (v/v) methanol/10% (v/v) acetic acid. 
The second half was developed as a zymogram gel (Wei et al., 2016). To accomplish this, 
the gel was washed twice for 30 min in  buffer containing 2.5% Triton X-100 (renaturing 
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buffer; Life Technologies, Carlsbad, CA), followed by washing twice for 1 h in buffer 
containing 20 mM Tris-HCl, pH 7.5 (developing buffer; Life Technologies, Carlsbad, CA). 
Gel A was then incubated in developing buffer supplemented with 1% casein (Sigma, St. 
Louis, MO) at 37°C for 1.5 h. After washing with water for 2 min, gel A was stained with 
0.1% (w/v) Coomassie Brilliant Blue in 40% (v/v) methanol/10% (v/v) acetic acid for 24 
h. Both gels A and B were destained in 40% (v/v) methanol/10% (v/v) acetic acid until 
optimal contrast was achieved. 
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Figure 8. Schematic of the SDS-PAGE and casein zymography procedures.  
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3.1.3. LC-ESI-MS/MS 
The gel halves were aligned, and the protein displaying enzyme activity was excised from 
the duplicate lanes, and the matching band in gel B was also excised in duplicate. The 
proteins were digested in-gel with sequencing-grade trypsin, and the peptides were eluted 
and separated by in line C18 chromatography. The amino acid sequences of the peptide 
ions were obtained with an LTQ Orbi-trap mass spectrometer (ThermoFinnigan, San Jose, 
CA). The b- and y-ion spectra were searched against a database of R. aeria F0474, 
supplemented with decoy proteins as well as the three Rothia subtilisin genes  published 
previously (Wei et al., 2016). The filter settings selected were X-corr values > 2.2 and 3.5 
for Z = 2, and 3, respectively. The deltaCn and peptide probability settings were >0.1 and 
<0.01, resp., as previously applied (Wei et al., 2016). 
 
3.1.4. Preparation of mouse chow admixed with Rothia bacteria 
Mouse chow with bacteria was prepared in advance of the in vitro experiment. A 1 g of 
powdered mouse chow (2018, Envigo, Cambridgeshire, UK) containing 18% crude 
proteins which have approximately 25 mg gliadin in 1 g. The chow was mixed with 
lyophilized R. aeria bacteria at a ratio of 1.59x107 cells/gram chow. The mixture was added 
to a 2 ml Eppendorf tube and water was added incrementally to form a slurry. The chow 
slurry was dried in the SpeedVac (SpeedVac plus SC110 A, Savant, NY, USA) for 3 hr. 
The resultant pellet was removed from the Eppendorf tube and was visually similar to an 
original pellet.  
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3.1.5. In vitro digestion of gliadins in chow by Rothia bacteria 
Mouse chow pellets supplemented with R. aeria (Ra+) or without (Ra-), were crushed and 
suspended in a 1 ml volume of water. After incubation at 37oC for 0, 2 and 4 h, the 
supernatants were collected and boiled for 10 min and then mixed with 60% ethanol to 
extract the gliadins by shaking (40 rpm) at room temperature for 1 hour and centrifuged 
(2000 g x 10 min, 4°C). Aliquots (10 µl) of 60% ethanol-extracted sample supernatants 
were loaded onto SDS PAGE gel. Gliadin degradation was assessed by immunoblotting 
with an anti-gliadin polyclonal antibody (Sigma A1052, 1:500 dilution).  
 
3.1.6. In vivo digestion by Rothia bacteria 
Nine week-old female Balb/c mice (n=9 mice/group) were fed with chow with and without 
added R. aeria bacteria as control. Mice were euthanized 2 hr after the complete ingestion 
of the food pellets. The gastro-intestinal tissues were removed intact. The small intestines 
were divided into three parts, the duodenum, the jejunum, and the ileum at a 1:3:2 length 
ratio, respectively (Figure 9). The stomach and small intestine lavage content were 
collected and centrifuged (2,000g, x 10min, Thermo Scientific legend X1R, USA). The 
supernatants were collected and boiled (100°C, 10 min), then mixed with 60% ethanol to 
extract the gliadins by shaking (40 rpm) at room temperature for 1 hr and then centrifuged 
(2,000 g x 10 min, 4°C). The supernatants were collected and protein concentrations 
determined with the BCA protein assay. Samples were standardized for protein content. 
Gliadin degradation was assessed by SDS PAGE and immunoblotting with an anti-gliadin 
antibody (Sigma). Densitometry analysis was carried out by drawing equal size boxes 
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around the bands in the gel of 37 kDa and 50 kDa. The data were corrected for intensity 
level after subtracting the background by selecting a blank area in the image.  The analyses 
were carried out using Quantity one software.  Hydrolysis of gliadin immunogenic gluten 
epitopes was assessed with the R5 ELISA assay (RIDASCREEN Gliadin-R-Biopharm AG 
#R7001). 
 
 
 
 
 
 
 
 
 
Figure 9.  Image of a mouse stomach-small intestinal preparation 
 
3.1.7. Statistics 
Data were analyzed using SPSS 17.0 software and were computed with GraphPad Prism 
8. Mann–Whitney test (non-parametric, when samples failed normality or equality of 
variance statistical tests) were used to test for statistical significance between groups. The 
data were represented as average ± standard error of mean (SEM), a value of p < 0.05 was 
considered to be statistically significant. 
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3.2. Part II 
3.2.1. Rothia and Bacillus culture  
Rothia aeria strain “WSA-8” (lab isolates), and two Bacillus subtilis strains,  strain 1A1 
and mutant strain WB800N (nprE aprE epr bpr mpr::ble nprB::bsrΔvpr wprA::hyg 
cm::neo; NeoR) were cultured on Brucella agar plate (Hardy Diagnostics, Santa Maria, 
CA) at 37oC for 48 hours under aerobic conditions. The bacterial cells were harvested from 
the plate and suspended in sterilized PBS with an OD620 = 5.0. Aliquots (150 µl) in 
duplicates of the suspension were centrifuged (2,000 x g, 10 min, at 4oC), and dried. 
 
3.2.2. Rothia and Bacillus cell-associated enzyme activities 
The dried bacterial cell sediments were suspended in 15 µl zymogram sample buffer (1x). 
The samples were analyzed on a 6% non-denaturing gel with or without gliadin added. 
After electrophoresis at a constant voltage of 120V in cold room (4°C) for 2 hours, the gel 
without gliadin was stained with Coomassie brilliant blue. The gel with gliadin (zymogram 
gel) was renatured by washing (30min, 2x) in buffer containing 2.5% Triton X-100, The 
gels were developed in 20 mM Tris-HCl at pH 3.0 or pH 7.0, followed by Coomassie 
Brilliant Blue staining and distaining. 
 
3.2.3. Stability test 
Sub-A (Sigma 5380) was dissolved in various solutions at a concentration of 1 mg/ml. The 
solutions included:  PMSF (1 µg/ml) in deionized water, 31mM HCl (pH 1.5), sodium 
carbonate buffer (0.1 M Na2CO3 mixed with 0.1 M NaHCO3, pH 10), and 50% DMSO. 
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Each solution containing enzyme was kept on ice (0°C) for 1 hr, and aliquots were taken 
for protein content analysis by SDS-PAGE and activity analysis by casein zymography and 
by spectrophotometry using Suc-AAPF-pNA as the enzyme substrate as described below. 
To test the effect of incubation time on the stability and activity of Sub-A, the enzyme was 
dissolved in deionized water to 1 mg/ml and incubated at 37°C for 0, 0.5, 1, 3, 6, 24, 48, 
or 72 hr. Aliquots were collected and stored at -80°C for protein content and activity 
analysis.  
To test the effect of different temperatures on the stability and activity of Sub-A, 
the enzyme was dissolved in deionized water to 1 mg/ml and incubated for 10 min at 37, 
40, 50, 60, 70, 80, 90, or 100°C using a Heat Block (VWR Scientific). The temperature 
was monitored by an infrared thermometer (Traceable, Fisher). Aliquots were collected 
and stored in -80°C for protein content and activity analysis.  
 
3.2.4. SDS-PAGE  
The samples (25 µg protein) were mixed with Bis-Tris sample buffer without DDT. After 
boiling for 5 min, the samples were loaded onto a NuPAGE 4-12% Bis-Tris gel (Invitrogen, 
Novex). Electrophoresis was performed at a constant voltage of 120 V for about 1 hr at 
room temperature. The gels were either silver stained essentially as described (Chevallet 
et al., 2006), or stained with 0.1% (w/v) Coomassie Brilliant Blue in 40% (v/v) 
methanol/10% (v/v) acetic acid for 24 hr, and de-stained in the same solution without dye.  
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3.2.5. Casein zymography  
Casein zymography was performed as previously described (Wei et al., 2016). The sample 
aliquots (5 µg protein) mixed with zymogram sample buffer not containing a reducing 
agent were loaded non-boilied onto a custom-made non-reducing 12% SDS-PAGE gel. 
After electrophoresis under non-reducing conditions at a constant voltage of 100V at 4°C 
for 2 hr, the gel was renatured by washing (30min, 2x) in buffer containing 2.5% Triton X-
100, followed by washing twice in developing buffer containing 20 mM Tris-HCl (pH 7.5), 
and then the gel was incubated in the developing buffer supplemented with externally 
added 1% casein, as described in Section 3.1.2.                                                                                                                                                                                                                           
 
3.2.6. Hydrolysis of para-nitroanilide-derivatized substrate 
Para-nitroanilide (pNA)-derivatized substrate (Suc-AAPF-pNA) was obtained from Sigma 
where Suc is N-succinyl and A is alanine, P is proline and F is phenylalanine. The substrate 
were dissolved in 75% DMSO at 10 mM.  The aliquots (50 µl) of Sub-A solution were 
suspended in 150 µl of PBS (pH 7.0) and diluted to 0.25 µg/ml. The mixture of 200 µl were 
added in triplicate to a 96-well microtiter plate (Costar 3596, Corning, NY, USA) 
containing 4 µl of 10 mM Suc-AAPF-pNA (0.2 mM final). Substrate hydrolysis was 
spectrophotometrically monitored at 405 nm, 37°C for 1 h with 10 min intervals kinetically 
using a Genios microtiter plate reader (Tecan, Männedorf, Switzerland).  
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3.3. Part III 
3.3.1. Modification of Sub-A 
Sub-A from B. licheniformis (Sigma 5380) was modified by PEGylation, and 
microencapsulation as schematically represented in Figure 10. 
 
 
 
 
 
 
 
 
 
 
Figure 10. Schematic representation of the pharmaceutical coating procedure applied 
to Sub-A. Adopted from: Radi et al., Med. Chem. Commun. 2016, 7, 1738-1744.  
 
3.3.2. PEGylation of Sub-A  
PEGylation of Sub-A was performed using the methods reported by Castellanos (Castillo 
et al., 2006) and Mabrouk (Mabrouk 1994). Sub-A (40 mg) and activated mPEG (120 mg, 
5 kDa) were dissolved in 20 ml of 0.1 M sodium borate buffer (pH 9.2) at an approximate 
molar ratio of 1:3 (solvent-accessible lysine residues in Sub-A to mPEG) and stirred for 3 
hr at 4°C. The reaction was quenched by the addition of 20 ml of 0.1 M potassium 
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phosphate buffer (pH 7.0). Non-reacted mPEG and buffer salts were removed by dialysis 
using membranes with a cut-off of 8 kDa (Spectra Medical Industries, Laguna Hills, CA) 
against 1 L of miliQ water for 24 hr. The PEGylated Sub-A (Sub-A-mPEG conjugates) in 
aqueous solution was frozen in -80°C for 30 min and lyophilized (Virtis FM 25 EL, NY, 
USA) at a condenser temperature of -70°C and a pressure of <20 millitorr. Lyophilized 
protein powders were kept at -20°C until used in the experiments.  
 
3.3.3. Validation of PEGylation efficiency  
The PEGylation efficiency of Sub-A was evaluated with the fluorescamine method for 
folded proteins (Al-Azzam et al., 2005; Karr et al., 1994; Stocks et al., 1986) and the 
TNBSA method for unfolded proteins  (Al-Azzam et al., 2005). 
 
Fluorescamine Assay 
The average number of free amino groups in the PEGylated Sub-A surface was determined 
by a fluorescamine method (Al-Azzam et al., 2005; Karr et al., 1994; Stocks et al., 1986). 
Fluorescamine, a heterocyclic dione, reacts with primary amines to form a fluorescent 
product. The fluorescence of a solution containing protein plus fluorescamine is 
proportional to the quantity of free amine groups present. Unmodified and mPEG-modified 
Sub-A were dissolved in PBS (pH 7.4) at 0, 0.1, 0.2 and 0.3 mg/ml, and aliquots (150 μL) 
were pipetted into each well of a 96-black-well microplate (flat bottom) in triplicate. The 
fluorescence was measured immediately after mixing with 50 μL of 0.3 mg/mL 
fluorescamine solution (in acetone) at an excitation wavelength of 360 nm, and an emission 
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wavelength of 465 nm. Fluorescence intensity values were plotted versus the Sub-A 
concentrations. The percentage of mPEG modification was calculated using the formula 
[1-(slope of Sub-A-mPEG/Sub-A)] x 100. 
 
TNBSA Assay  
Since fluorescamine cannot react with unexposed primary amines of folded proteins, the 
TNBSA (2, 4, 6-Trinitrobenzenesulfonic acid) method (Habeeb 1966) was used to further 
estimate the extent of mPEG modification. The protein is unfolded in HCl and SDS, 
rendering all amino groups solvent accessible. The assay was performed as follows: Sub-
A-mPEG and Sub-A were dissolved in 1 ml of 0.2 M sodium bicarbonate buffer (pH 8.5) 
to achieve concentrations between 0.1 and 0.4 mg/ml. To these solutions and buffer blanks, 
0.25 ml of 0.01% TNBSA (w/v), 0.25 ml of 10 % SDS solution (w/v), and 0.125 ml of 1 
N HCl were added. The mixtures were incubated at 37°C for 2 h, and their absorbance at 
335 nm was subsequently determined (Genios microtiter plate reader, Tecan, Männedorf, 
Switzerland). The absorbance values were calibrated by subtracting the values of buffer 
blanks and were then plotted versus the Sub-A/ Sub-A-mPEG concentration. The 
percentage of mPEG modification was calculated using the formula [1-(slope of Sub-A-
mPEG/Sub-A)] x 100. 
 
3.3.4. Micro-encapsulation of PEGylated Sub-A  
Micro-encapsulation of PEGylated Sub-A was performed essentially as described 
(Castellanos et al., 2005). Sub-A-mPEG (10 mg) was dissolved in 0.5 ml of 0.2 M sodium 
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bicarbonate buffer (NaHCO3, pH 10.0), and poly-lactic glycolic acid (PLGA) (90 mg) was 
dissolved in 0.5 ml acetone. The two solutions were mixed, vortexed, followed by addition 
of 3 ml of light liquid paraffin and 0.05 ml of Span 80 while with vortexing. The mixture 
was placed in a 40 ml beaker while stirring at 500-700 rpm for 3 hr at room temperature 
until the acetone evaporated completely, resulting in the formation of microcapsules. The 
formed microcapsules were harvested by centrifugation (2 min, 7,000 rpm), washed (5x) 
in petroleum ether (40–60o grade), and dried at room temperature for 24 hr.  
 
3.3.5. Acid and pepsin challenge test 
To test the stability and activity of Sub-A and Sub-A-mPEG after incubation under acidic 
conditions, the enzymes were dissolved in diluted gastric buffer (pH 3.0, Sigma 01651) at 
a concentration of 0.25 mg/ml.  After incubation at 37°C for 1 hr, the solutions were 
neutralized and diluted by adding an intestinal buffer (pH 7.0, Sigma 53757). The enzymes 
(0.25 µg/ml) were then tested for activity using Suc-AAPF-pNA as the substrate. 
To test the stability and activity of Sub-A and Sub-A-mPEG-PLGA after incubation with 
pepsin under acidic conditions, the effect of pepsin on the modified Sub-A enzyme (a 
second challenge to the enzyme) was tested by pre-incubating the enzyme with pepsin 10 
mg/ml at acid conditions, Sub-A enzymes were then tested for activity using Suc-AAPF-
pNA as the substrate. 
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3.3.6. Enzyme activity assessment using Suc-AAPF-pNA  
The aliquots (50 µl) of Sub-A, Sub-A-mPEG, or Sub-A-mPEG-PLGA were added to 150 
µl of PBS (pH 7.0) and diluted to to 0.25 µg/ml. The 200 µl aliquots were added in triplicate 
to a 96-well microtiter plate (Costar 3596, Corning, NY, USA) mixed with 0.2 mM Suc-
AAPF-pNA and changes in absorbance were monitored spectrophotometrically, as 
described in detail in section 3.2.6. 
 
3.3.7. Enzyme activity assessment using gliadins  
Sub-A and Sub-A-mPEG-PLGA were dissolved in diluted HCl buffer (pH3.0) to 1 mg/ml 
and incubated at 37°C for 0, 3 and 24 h. Gliadin hydrolysis activity of each pre-treated 
enzyme sample were determined by incubating a 40 fold dilution of the pretreated enzyme 
(25 µg/ml) samples with gliadin (250 µg/ml) in PBS (pH 7.0) at 37°C. Gliadin degradation 
was monitored after 0 and 1 h of incubation in 100 µl sample aliquots subjected to 4-12 % 
SDS PAGE.  
 
3.3.8. Assessment of enzyme activity in vivo   
All animal experiments were conducted using institutionally approved protocols at Boston 
University (IACUC) and (American Council on Animal Care standards and Animal 
Research: Reporting in Vivo Experiments guidelines). The animals were housed in a 
controlled environment (22°C, 12 h day/night cycle) with ad libitum food and drink access. 
For the in vivo experiment, 1 g of powdered mouse chow (2018, Envigo, Cambridgeshire, 
UK) was added into a 2 ml Eppendorf tube and mixed incrementally with 400 to 600 µl 
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sterilized water by packing layer by layer to form a pellet, where a 200 µl-yellow pipette 
tip was inserted to cast a hollow center for later loading of the enzyme samples (Figure 11). 
The chow pellets were dried in the SpeedVac (SpeedVac plus SC110 A, Savant, NY, USA) 
for 3 hours. Sub-A or Sub-A-mPEG-PLGA were added in an amount of 0.2 mg to the 
center of the pellets, which were then closed with the mice chow paste. 
 
 
 
 
Figure 11. Method for the preparation of mice chow with added enzyme 
(Sub-A or Sub-A-mPEG).  
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Balb/c female mice (9 weeks old, n=30) were acclimatized for a week. After 18 hr 
of fasting, the mice were fed for 3 hr as follows: Group I (n=9): chow pellets without added 
enzyme; Group II (n=9): chow pellets with Sub-A; and Group III (n=9): chow pellets with 
Sub-A-mPEG-PGLA; and no food controls (n=3). The mice were then euthanized, and 
stomach contents were collected and suspended in 2 ml of sterile water, and boiled (100°C, 
10 min), and then centrifuged (2,000 g, 2 min, at 4°C). The suspensions were collected and 
then mixed with 60% ethanol to extract gliadin peptides. After shaking (40 rpm) at room 
temperature for 1 h, the mixtures were centrifuged (2,000 g x 10 min, 4°C), and the ethanol 
extracted sample supernatants were collected. The protein content of the supernatants were 
determined by using the BCA protein assay kit (Sigma).  
The survival of immunogenic gluten epitopes of the extracted samples were 
subsequently analyzed using the ELISA-R5 assay kit (RIDASCREEN Gliadin, R-
Biopharm, and Darmstadt, Germany). The microtiter plate wells were blocked with 1 % 
milk in PBS (200 µl). After incubation at room temperature for 1 h, the plate was washed 
three times with PBST (PBS + 0.5 % Tween-20). The protein concentration of the stomach 
samples were adjusted to 160 µg/ml, and diluted 3,200-fold in dilution buffer. This dilution 
factor was determined to reduce gliadin levels to concentrations falling within the linear 
part of the standard curve.  Aliquots of 100 µl of each of the diluted samples, as well as the 
controls of 0 ppb and 80 ppb gliadin standard solutions included in the kit, were added to 
each well, following the instructions provided by the manufacturer.  
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3.3.9. Statistics 
Data were analysed using SPSS 17.0 software and were computed with GraphPad Prism 
8. Standard one way ANOVA (non-parametric, when samples failed normality or equality 
of variance statistical tests) were used to test for statistical significance between groups. 
The data were represented as ± standard error of mean (SEM). A value of p < 0.05 was 
considered to be statistically significant. 
  
42 
 
4. RESULTS 
4.1. Part I 
4.1.1. Isolation and identification of the R. aeria enzyme 
The genes of the already identified R. mucilaginosa subtilisin enzymes (Wei et al., 2016) 
are ROTMU0001_0241, ROTMU0001_0243, and ROTMU0001_0240. To identify the 
gluten-degrading enzyme from R. aeria a large SDS gel (16x20 cm) was used instead of a 
mini SDS gel (8x8 cm) to achieve better protein separation. A low percentage gel (6%) 
facilitated separation of proteins with molecular weights >50 kDa. It was known from 
previous studies that the R. aeria enzyme migrated at approx. 75 kDa (Zamakhchari et al., 
2011). 
The big gel results are shown in Figure 12. The zymogram gel part (Figure 12A) 
provided evidence for a single band with enzyme activity migrating at ~75 kDa, and the 
matching non-denaturing Coomassie-stained gel in Figure12B showed a major band 
migrating at the same position. As a control, the proteins were also analyzed on a 
denaturing gel, showing substantially more protein bands migrating into the gel (Figure 
12C). The bands labeled 1-4 in 12A and 12B were excised and subjected to mass 
spectrometric analysis. They were searched against a Rothia database, comprising the 
whole genome of R. aeria supplemented with R. aeria, R. mucilaginosa and R. 
dentocariosa subtilisin genes.  
As expected, more than one protein was identified in each band. In total 3, 4, 23 
and 23 proteins were identified by >2 unique peptides in bands 1, 2, 3 and 4, respectively. 
Identification of a protein by at least two peptides is a criterion typically applied for protein 
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identification by mass spectrometry (Zhao and Lin 2010). The most prominent protein in 
all four samples, identified with high confidence, was peptidase S8, KGJ00122.1. It was 
represented by 32, 30, 33 and 41 unique peptides, in the four excised bands, resp. A blast 
search of KGJ00122.1 revealed that it is 99% homologous to a R. aeria protein annotated 
as glycerol-3P-ABC transporter in NCBI (BAV86562.1) 1*. Sequence analysis of 
BAV86562.1 however revealed that it is a subtilisin family member, because it contains 
the cd07474 domain, representing the peptidase S8 family domain (Figure 13). Therefore, 
it appears that this protein is miss-annotated in the database as an ABC transporter. The D, 
S and H amino acids of the catalytic triad present in this domain are underlined.  
                                                 
1 * Enzyme identification was carried out by Dr. Helmerhorst  
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Figure 12. Identification of the gluten degrading enzyme from Rothia aeria. A, gel part 
developed as a zymogram gel using externally added casein as the enzyme substrate to 
visualize bands with enzyme activity (indicated with an arrow); B, native PAGE gel part 
stained with Coomassie Brilliant Blue; C, SDS-PAGE mini gel stained with Coomassie 
Brilliant Blue. Bands 1-4 were excised and subjected to mass spectrometric analysis.  
 
>BAV86562.1 glycerol-3-phosphate ABC transporter [Rothia aeria] 
MAITAGLPATAAPAGDPDTPVAQDIARNSREHAVLSDSMKKAEGNIPVFVQFKG
KGAYEQTQSPAVLANKQAPTNKQAEVQAIKTQVQSQAQAAAQSTGAKTLYTTH
NIMRGVALQGDAAQIRALANNPEVERITPIVPKKKQNAGSVVDTGAAENWARE
NSGYTGKDVKIAVVDSGIDYTHADFGGPGTVEAFNKATKLTEMPAADSGLY
DAKKYIGGYDLVGDSYDGTNQTAPDNNPIDCSAGGHGTHVAGTAAGYGVN
45 
 
QDGTTFRGDYSKLTAEQLNQMKIGPGAAPEAQLYSFRVFGCTGTTGVVVQ
ALDRTLDPNGDGDFSDRANIVNLSIGGEFSPPDDADAYAVESLNRQGVLAVV
SAGNATDYYGRGDTYSDSGQPANAVSALTVANSIGSSYAVDSMEIQAPANVA
GKVPGDYTVSYTYTGAKPEALTGTVVTPSESNKFGCEAFSAEDAAKIKDKW
VFLEWANADGSLPCGSKVRFDNVEKAGGKGVVLSSEEEKPALPIGGNESIPG
FRVAKSASAKVREAAANGELKVRLGTDLKESLRVPSNKKDQLTASSARGYH
GTYGYTKPDVAAPGNNISSARVGTGTDGISYTGTSMSAPFAAGVAAQVLQA
NQSYGPTQLKAAIMNSANHDVRTADGNVYAVDRVGSGRIDAKAAAETKVLL
YNADRPAQVSQTFGVLEYAVNEGKQTLTREMTVENFDSHTHTYNISYAGSTDM
PGVEFSLPSNITVNPGEKKNFTVTITIDPAAMEKTMDPAMEKTHNSVDPYGDGTE
LVPEQYRQFIASESGRILLTEGAATLRAPIHAAPKPASAMKVEGSSVEIPAGEHQA
NLKLTGTELNQRGYKSLLGAFEHGASIERTSPVKLDVSSNAKANMQHVGAASTA
PALKASGGNPNDGLLAFGISTWANWDVVSTENTFTVNIDTDGNNRADYMLVTD
RAKGIDFPIVRLYGYKNGNLEQIAYYPLNNAWGDTDTNMMDSNALVMAVPLKD
LGLSAEKTKDIKYSVSATTQYAWTNVSETGWINYRPFDPKLWFSGTAATVPGFF
ADAPSSELVAHRAEGATDVKALFLHMHNTTGDLSGLNGAAGNRAQVLEVTEQQ
QLDPAPSRFTDVPAENQFYAEINWLAQRRITTGYPDGTFRPGENVERGAMAAYF
YRLAGTPQFTAPDNPTFSDVPKSHPFYKEIEWMAARGITTGYGDGTFRPSASVNR
DAMAAFFYRYANSPQFAAPAASPFKDVPANSQFYKEIAWLAEQGITKGWDDGT
YRPGEPIHRDAMAAFLYRYSDKVLK 
 
Figure 13. Amino acid sequence of R. aeria BAV86562.1. In bold: domain cd07474 
representing the peptidase S8 family domain in Vpr-like proteins. BAV86562.1 is not an 
ABC transporter protein as its name suggests and it lacks the LSGGQ domains 
characteristic of the ABC transporter family Underlined: D, S and H residues comprising 
the catalytic triad of the subtilisin enzyme.  
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4.1.2. In vitro gluten in chow degradation by R. aeria bacteria 
The aim of this experiment was to investigate if Rothia can digest gluten proteins present 
in food. First, it was investigated if gluten can be degraded by Rothia in vitro by mixing 
the suspended chow with Rothia bacteria. Chow containing gliadins were mixed with 
lyophilized R. aeria bacteria at a ratio of 1.59x107 cells/gram chow in a 1 ml volume of 
water. After incubation at 37oC for 0, 2 and 4 hours, the particles in the mixture were 
precipitated, and proteins in the 60% ethanol-extracted sample supernatant separated by 
SDS PAGE and immunoblotted with an anti-gliadin antibody. As shown in Figure 14, 
gliadins were stable in food incubated in the absence of R. aeria, but the main bands at ~37 
and ~50 kDa (indicated with arrows) degraded within two hr in the presence of R. aeria.  
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Figure 14. Enzymatic degradation of gliadins in mouse chow in vitro detected by 
immunoblotting. Mouse chow was supplemented with R. aeria (Ra+) and without (Ra-) 
and incubated at 37oC for 0, 2 and 4 hr. Aliquots (10 µl) of 60% ethanol-extracted sample 
supernatants were loaded. Lane1: Gliadin control (Gli, 15 µg); Lane 2: Ra (-) at 0 hour; 
Lane 3: Ra (-) at 2 hr; Lane 4: Ra (-) at 4 hr; Lane 5: Ra (+) at 0 hr; Lane 6: Ra (+) at 2 hr; 
Lane 7: Ra (+) at 4 hr, blue (arrow) points to the gliadin bands at 37 and 50 kDa. 
 
4.1.3. Assessment of chow distribution 2h after ingestion 
In a first experiment, two groups of mice (n=2 per group) were fasted for 16 hr and fed 1 
g chow without or with lyophilized R. aeria bacteria (OD620 200, 2.4x10
10 CFU). Both 
groups of mice ingested the chow, regardless of whether Rothia was added or not. After 2 
hr digestion, the mice were euthanized and the contents of the stomach and the small 
intestine were collected and suspended each in 4.5 ml of water. A BCA assay was created 
to determine the protein concentration of the samples, and the amount of protein present in 
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each of the samples was determined by multiplying by 4.5. Based on the numbers obtained, 
it was determined that approximately 64% of the food bolus was present in the stomach 
and 36% in the small intestine (duodenum, jejunum and ileum), as shown in Figure 15. The 
proteins detected in the endogenous intestinal fluids was assumed to be negligible 
compared to the protein contained in the chow. 
 
Figure 15. Distribution of the chyme in the stomach and the small intestines. The 
protein amount of the harvested stomach contents (red) and small intestine (orange) 
contents, n=4 were determined from the protein concentrations obtained by BCA method 
multiplied by the sample volume divided by the total protein amount in both the stomach 
and intestines combined multipled by one hundered. 
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4.1.4. In vivo gluten degradation by R. aeria bacteria 
To obtain insights into the mice palatability and acceptability of R. aeria-supplemented 
chow, the ingestion time for 1 g of chow, and the detectability of gliadins in the chow-
containing chyme harvested from the gastrointestinal tract, a pilot experiment was 
conducted with four mice (n=2 per group) which were fed with 1 g chow with or without 
lyophilized R. aeria (OD620 200, 2.4x10
10 CFU). The mice ingested the 1 g chow, with or 
without Rothia added, in about 1 hr. After digestion for 2 more hr, the mice were 
euthanized, the stomach and duodenal contents were harvested, suspended in PBS, and 
immediately boiled for 10 min. Aliquots containing equal amounts of protein from ethanol-
extracted sample supernatants were loaded onto an SDS PAGE 4-12% gel (Figure 16A). 
The amount of gliadin in the samples were determined by immunoblotting with an anti-
gliadin-peroxidase conjugated antibody (A1052, Sigma, Darmstadt, Germany). The results 
showed that gliadins were detectable in the stomach, but not in the small intestinal samples, 
of both the control and the R. aeria-fed mice (Figure 16B). Since the duodenal contents of 
the mice were small, potentially leading to errors in gliadin content calculations, the next 
experiments were conducted with the gastric extracts only. 
 
 
 
 
 
 
50 
 
 
 
 
 
 
 
Figure 16. Analysis of gliadin in gastro-intestinal samples by SDS-PAGE (A) and 
immunoblotting (B). Aliquots (63 µg protein) of the gastro-intestinal samples with R. 
aeria (Ra+) and without (Ra-) bacteria were loaded on two 4-12% SDS-PAGE gels. After 
electrophoresis at 120 V, the gels were either stained with Coomassie brilliant blue (A), or 
processed by immunoblotting with an anti-gliadin antibody (B). Lane 1: Protein standard, 
5 µl; Lane 2: Gliadin control (Gli, 25 µg); Lane 3: Stomach Ra (-); Lane 4: Stomach Ra 
(+); Lane 5: Duodenum Ra (-); Lane 6: Duodenum Ra (+); Lane 7: Jejunum Ra (-); Lane 
8: Jejunum Ra (+); Lane 8: Ileum Ra (-); Lane 9: Ileum Ra (+). Blue (arrow) pointed to the 
gliadin bands at 37 and 50 kDa. 
 
4.1.5. Gliadin degradation by R. aeria in vivo by immunoblotting 
A subsequent in vivo digestion experiment was carried out with 9 female mice per group. 
The control group was fed with mice chow without R. aeria for 1 hr, and euthanized after 
2 hr. The experimental group received mice chow with R. aeria, for 1 hr and the mice were 
also euthanized after 2 hr. All mice ingested the chow in less than 1 hr. Gliadin levels in 
the stomach samples from mice fed with and without R. aeria (n=9), are shown in Figure 
17. Densitometric analysis of the major gliadin bands at 37 and 50 kDa was carried out to 
quantitate the amount of gliadin remaining in the stomach contents in both groups. Results 
showed that gliadin levels remaining in the chow of mice fed without Rothia were 25876.5 
AU whereas the levels remaining chow of mice fed with Rothia supplementation were 
A B 
1    2    3    4     5     6    7     8    
9   10   
1     2     3     4      5      6      7     8    
9     10   
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20646.8 AU. Figure 18A shows the average of the remaining amount of gliadin in each 
group whereas Figure 18B, shows the distribution of the individual data points. It can be 
concluded that gliadin degradation in the mice chow supplemented with R. aeria were 
reduced by 20.2% as compared to the control mice.  
 
 
Figure 17. Gliadin degradation in vivo by Rothia bacteria. Two groups of mice (M) 
were fed chow without R. aeria and chow with R. aeria.  Aliquots (160 µg protein) of the 
gastric samples with (Ra+) and without (Ra-) bacteria (n=9/group) were subjected to 
immunoblotting with an anti-gliadin antibody. Lane 1, 2, 3; 10, 11, 12; 19, 20, 21: Gliadin 
control (5, 1 and 0.2 µg), respectively; Lanes 4, 6, 8, 13, 15, 17, 22, 24, 26: the nine mice 
fed chow without R. aeria bacteria Ra (-); Lanes 5, 7, 9, 14, 16, 18, 23, 25, 27: the nine 
mice fed chow with R. aeria bacteria Ra (+). The blue (arrow) pointed to the gliadin bands 
at 37 kDa. 
  
Ponceau S stain  
(Loading control) 
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Figure 18. Densitometric analysis of the major gliadin protein bands boxed in Figure 
17. A) the average of the remaining gliadin amount and B) the distribution of the data 
points in each group. The data represent three independent experiments and the error bars 
+/- SEM. *p < 0.05. 
 
4.1.6. Gliadin epitope degradation by R. aeria in vivo by ELISA 
To investigate the survival of immunogenic epitopes in the harvested stomach samples an 
ELISA test was carried out using R5 monoclonal antibody, specifically recognizing the 
QQPFP, QQQFP and LQPFP immunogenic epitopes (Valdes et al., 2003). The average 
values found for the mice fed with chow supplemented with R. aeria group is 16.8 ppm 
and for the control group 25.1 ppm. The gliadin immunogenic epitopes detected with 
ELISA results provided evidence that gliadin epitopes were statistically significant reduced 
32.6 % as compared to the control mice. The distribution of the individual data points is 
shown in Figure 19. 
 
 
 
A B 
* 
* 
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Figure 19. Epitope survival in gluten after in vivo digestion with R. aeria bacteria.  A 
monoclonal R5 antibody-based ELISA kit was used to detect the survival of epitopes in 
stomach samples from mice fed with chow supplemented with R. aeria (Ra+) and 
without (Ra-). The experiment was performed according to the manufacturer’s 
instructions. The data plotted are with R. aeria (Ra+) and without (Ra-). The data 
represents three independent experiments and the error bars average +/- SEM. **p < 
0.01. 
 
4.2. Part II 
4.2.1. R. aeria and B. subtilis comparison in gluten-degradation 
Subtilisins were first identified in Bacillus subtilis. Our previous studies have demonstrated 
that subtilisin from B. subtilis, like subtilisin from R. mucilaginosa, can degrade gliadin-
derived enzyme substrates and eliminate immunogenic epitopes (Wei et al., 2016). Here, 
the gliadin-degrading activities of R. aeria and B. subtilis strain A1A were compared in a 
zymogram gel, along with an enzyme knockout of B. subtilis, strain WB800N. The result 
confirm that B. subtilis can cleave gliadins, and that the digestion is absent in a mutant not 
expressing subtilisins (Figure 20). Note further that the enzyme activity of both the R. aeria 
and B. subtilis enzymes is reduced at more acidic pH conditions, an issue which is 
addressed in more detail in Part III. 
** ** 
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Figure 20. R. aeria and B. subtilis comparison in gluten-degradation. Bacterial cells 
were suspended in 1ml of PBS at concentration of OD620nm=5.  Aliquots (150 µl) were 
centrifuged and the pellet was re-suspended in 20 µl zymogram sample buffer and loaded 
onto 6% zymogram gel (A), and 6% zymogram with gliadin substrate gel (B). After 
electrophoresis, the enzyme activity gel was washed two times with renature buffer and 
with developing buffer (pH 7 or pH3). After incubation at 37°C for 48 h, both gels were 
stained with Coomassie blue. Gel lanes 1, 5 and 9: MW standard; lanes 2, 6 and 10 (Ra): 
R. aeria; lanes 3, 7 and 11 (Bs): B. subtilis; lanes 4, 8 and 12 (Bsm): B. subtilis (enzyme 
knockout) mutants. 
 
Based on this result, and the absence of quantitative amounts of the R. aeria 
enzyme, all subsequent studies were carried out with the B. subtilis enzyme subtilisin A 
(Sub-A). During these experiments it was noted that the enzyme in aqueous solutions is 
highly unstable. Sub-A has an approximate molecular weight of 27 kDa. However, when 
the enzyme was dissolved at neutral pH, a band with a much lower molecular weight (<10 
kDa)  was observed (Figure 21A) To assess if these lower molecular weight bands 
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represented degradation fragments, the enzyme was dissolved in diluted gastric buffer at 
pH 1.5. Under those conditions, a protein band with the expected molecular weight of 27 
kDa was observed. The results suggested that Sub-A undergoes autolysis. The enzymatic 
activity of subtilisin incubated at 37°C decreased over time, and this loss of activity is 
likely due to autolysis (Figure 21B).  
 
Figure 21. Sub-A protein composition and activity. A, protein composition of the 
enzyme dissolved at pH 1.5, and at pH 7.0, analyzed by SDS-PAGE; B, enzyme activity 
over time, analyzed using Suc-AAPF-pNA as the enzyme substrate. Lane 1: MW; Lane 2: 
Sub-A in pH 1.5; Lane 3: Sub-A in pH 7.0. 
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4.2.2. The stability of Sub-A at different pH 
Sub-A dissolved in a solution containing PMSF or dissolved in 31mM HCL (pH 1.5) 
displayed the expected 27 kDa band, while low molecular weight bands (<10 kDa) were 
observed when the enzyme was dissolved in sodium carbonate buffer (pH 10), 50% DMSO 
or in milli-Q water (pH 6.0) (Figure 22A). The corresponding AAPF cleavage activities of 
the various enzyme preparations are shown in Figure 22B. The activity was highest when 
the enzyme was dissolved in 50% DMSO, sodium carbonate buffer (pH 10) or deionized 
water. The activity was virtually completely inhibited in the presence of PMSF and 31mM 
HCl (pH 1.5). Similar activity patterns were observed when the enzyme preparations were 
analyzed by zymography (Figure 22C). Clear bands indicate degradation of the casein 
substrate, evidencing enzyme activity. Activity was absent in the presence of PMSF and at 
low pH (lanes 2 and 3, resp.). 
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Figure 22. Sub-A enzyme activity in various solutions. Sub-A was dissolved in various 
solutions to 1 mg/ml and kept on ice. After 1 hr, aliquots were analyzed for protein content 
by SDS PAGE (A), for enzyme activity using Suc-AAPF-pNA as the enzyme substrate 
(B), and for enzyme activity in a casein zymogram (C). Enzyme amounts and 
concentrations tested in A, B and C were 25 µg, 0.25 µg/ml, and 5 µg, resp.  The solutions 
were: 1, PMSF (1 µg/ml) in deionized water; 2, dilute HCl (pH 1.5); 3, sodium carbonate 
buffer (pH 10); 4, 50% DMSO. In 5-7, subtilisin was dissolved in deionized water and 
incubated on ice, at room temperature, and at 37°C for 1h, resp. Solid arrows point to intact 
Sub-A, dashed arrow to its fragments. 
 
4.2.3. The effect of incubation time on the stability of Sub-A  
Figure 23 shows the effect of incubation time on the stability of Sub-A.  As shown in Figure 
23A, upon increasing incubation time, the low MW bands (<10 kDa) Sub-A disappeared.  
The cleavage activity towards Suc-AAPF-pNA was reduced by 4 fold with a max rate 
(𝝙OD405/min) of 20 to a rate of less than 5 after 6h incubation at 37°C (Figure 23B). 
Similar activity patterns were observed by zymography (Figure 23C).  
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Figure 23. Sub-A enzyme activity after incubation for various time intervals at 37°C. 
Stock suspension of Sub-A was prepared in deionized water yielding 1 mg/ml enzyme 
concentration. Aliquots of 25 µl and 5 µl were used for electrophoresis analysis to 
determine enzyme activity using incubation of 0, 0.5, 1, 3, 6, 24, 48, 72 hr. Enzyme 
amounts per lane in panel A were 25 µg and in panel B were 25 µg/ml and 5 µg in panel 
C. Lane 1: MW standard, lane 2: Sub-A dissolved at pH 1.5. 
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4.2.4. The effect of incubation temperature on the stability of Sub-A  
Figure 24 shows the effect of incubation temperature on the stability of Sub-A.  As shown 
in Figure 24A, upon increasing incubation temperature, the low MW bands (<10 kDa) Sub-
A disappeared. The cleavage activity of Sub-A enzyme towards Suc-AAPF-pNA was 
decreased by ~6 fold with max rate (𝝙OD405/min) from 60 to less than 10 as temperatures 
increasing from 37°C to 60°C,  and the activity was completely lost when the temperature 
was over 60°C (Figure 24B).  
 
Figure 24. Sub-A enzyme activity after incubation at various temperatures. Stock 
suspension of Sub-A was prepared in deionized water yielding 1 mg/ml enzyme 
concentration. Aliquots of 25 µl and 5 µl were used for electrophoresis analysis to 
determine enzyme activity using incubation at different temperatures (37, 40, 50, 60, 70, 
80, 90, 100°C) for 10 min. Enzyme amounts per lane in panel A were 25 µg and in panel 
B were 25 µg/ml. Gel lanes 1 and 2: MW standard, and Sub-A dissolved at pH 1.5. 
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4.3. Part III 
4.3.1. PEGylation of Sub-A  
The foregoing results showed that Sub-A is relatively unstable in aqueous solutions. In this 
part, the aim was to modify the Sub-A enzyme to increase its stability, and to protect the 
enzyme from acidic pH conditions as encountered in the stomach. Sub-A was modified by 
PEGylation with mPEG (Sub-A-mPEG).  As shown in Table 2 and Figure 25, the extent 
of mPEG modification in Sub-A-mPEG was 81.6% (~8 of 10 primary amines PEGylated) 
as determined by the fluorescamine method (A) and 55% (~6 of 10 primary amines 
PEGylated) determined by TNBSA method (B). The yield of Sub-A-mPEG, determined 
by the weight of the modified product (Sub-A-mPEG) / total weight of the agents before 
modification (Sub-A+mPEG) x 100%) was ~73 %, and the PEGylated products contained 
~34% (w/w) Sub-A (Table 1). 
 
 
  
 
Before modification 
(mg) 
After 
modification (mg) 
Yiel
d 
(%) 
Sub-A Conc. 
(%) 
Sub-A + mPEG 40 + 120 =160 116.6 ~73 ~34 
Sub-A-mPEG + 
PLGA 
10 + 90 =100 43.3 ~43 ~8 
Table 1. Modification of Sub-A 
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(A) Fluorescamine assay (B) TNBS assay 
Target Primary amine of folded 
protein 
Primary amine of unfolded 
protein 
Reaction product Fluorescent compound Chromogenic product 
Slope of Sub-A 14941 0.1153 
Slope of Sub-A-mPEG 2742.3 0.0514 
mPEG modification (%)  81.64 55.42 
*Number of PEGylated 
primary amine 
~8 ~6 
*Number of primary amine in Sub-A =10 
Table 2. Validation of PEGylation of Sub-A with two methods 
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Figure 25.  Assessment of the extent of Sub-A PEGylation by fluorescamine methods 
(A), and TNBSA method (B) , n=3.  
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4.3.2. Sub-A inactive at low pH 
Sub-A was highly active in hydrolyzing the Suc-AAPF-pNA substrate at neutral pH 
(intestinal buffer, pH 7.0) (Figure 26A). However, the enzyme was inactive at low pH 
(gastric buffer, pH 3.0). Even temporary exposure of the enzyme to low pH inactivated the 
enzyme, since activity could not be recovered upon transfer to neutral pH (Figure 26A). 
Both autolysis (Figure 21) and inactivation at low pH are a challenge for application of the 
enzymes in the digestive canal. Pharmaceutical modification was pursued to render the 
enzymes more resilient. 
 
4.3.3. PEGylated subtilisin-A (Sub-A-mPEG) activity 
Sub-A-mPEG retained enzymatic activity towards the Suc-AAPF-pNA substrate. Like 
Sub-A, mPEG was not active at low pH (Figure 26B). PEGylation of Sub-A had a dramatic 
effect on its autolytic activity, as shown in Figure 27. While Sub-A lost activity over time, 
the partial modification of the free amines by PEGylation virtually completely prevented 
autolysis. This can be explained by steric hindrance and partial modifications of the free 
N-termini in the enzyme structure, which could negatively impact Sub-A domains to fold 
towards the active site.  
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Figure 26. Activity of Sub-A and PEGylated Sub-A (Sub-A-mPEG), analyzed at pH 
7.0, at pH 3.0 and after pre-incubation at pH 3.0, n=3.  
 
 
 
 
 
 
-10
0
10
20
30
40
50
60
pH7 pH3 pH3->7 pH7 pH3 pH3->7
Subtilisin A Sub-A-mPEG
M
ax
 r
at
e 
(Δ
O
D
4
0
5
/m
in
)
A) B) 
66 
 
 
Figure 27. PEGylation protects Sub-A from autolysis. The activity of Sub-A and Sub-
A-mPEG was monitored over time at pH 7.0 (A) and pH 3.0 (B) , n=3.  
 
4.3.4. PLGA encapsulation of Sub-A-mPEG 
While autolysis could be effectively prevented with mPEG modification, the fact remained 
that Sub-mPEG is inactive at low pH, as shown in Figure 26B. As for Sub-A, temporary 
exposure of Sub-A-mPEG to low pH abolished the enzyme activity irreversibly. Therefore, 
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to obtain an enzyme preparation that could withstand gastroduodenal transit, further 
pharmaceutical modification of Sub-A-mPEG was needed. 
To protect Sub-A-mPEG from acidic insults, the enzyme was coated with PLGA. 
The yield of Sub-A-mPEG-PLGA, determined by the weight of the modified product (Sub-
A-mPEG-PLGA) / total weight of the agents before modification (Sub-A-mPEG+PLGA) 
x 100%, was ~43 %. The Sub-A concentration in Sub-A-mPEG-PLGA was ~8 % (w/w) as 
shown in Table 1.  
Significant improvements with respect to acid resistance of the enzyme were 
achieved by PLGA microencapsulation. In Figure 28A, the activity of all compounds, 
incubated at pH 7.0 and subsequently tested at pH 7.0 are compared. Sub-A processed 
without the addition of PLGA or mPEG (unmodified control) is active, but the activity 
decreased over time due to autolysis. This autolysis is prevented by mPEG modification, 
as evident from the sustained high activity of Sub-A-mPEG over time. PLGA-encapsulated 
Sub-A-mPEG (Sub-A-mPEG-PLGA) was also active, and retained activity over time. This 
is expected since after dissolution of the PLGA coating at neutral pH the active Sub-A-
mPEG enzyme is released.  
Then, the effect of PLGA coating on acid resistance was investigated. The 
compounds were pre-incubated in low pH buffer (pH 3.0), and then transferred to a buffer 
with a neutral pH. The Sub-A controls, as well as Sub-A-mPEG were inactive after the 
acid challenge. However, Sub-A-mPEG-PLGA was fully active after the challenge (Figure 
28B). These results indicate that the PLGA coating had protected the encapsulated Sub-A-
mPEG enzyme from denaturation during the acid exposure.  
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Figure 28. mPEG-PLGA modification renders Sub-A resistant to acid exposure. A, 
enzyme preparations pre-incubated at pH 7.0 and tested at pH 7.0; B, enzyme preparations 
pre-incubated at pH 3.0 and tested at pH 7.0, n=3.  
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4.3.5. Gliadin hydrolysis by Sub-A-mPEG-PLGA 
To assess the activity of Sub-A and Sub-A-mPEG-PLGA towards a gluten substrate, both 
enzyme preparations were exposed to acidic conditions at 37°C for 0, 3 and 24 hr, and then 
incubated with mixed gliadins at neutral pH at 37°C for 0 or 1 hr. Gliadin degradation was 
monitored by SDS-PAGE. Figure 29A shows the results obtained with Sub-A, and Figure 
29B the results obtained with Sub-A-mPEG. After acid exposure, Sub-A was inactive, as 
evidenced by the fact that gliadins remained intact after mixing with the enzyme. However, 
Sub-A-mPEG-PLGA show gliadin degredation after acid exposure for 24 hr, which 
indicates the enzyme was active after acid challenge, as shown in Figure 29B, lane 3, 5 and 
7. These results confirm that Sub-A-mPEG-PLGA can withstand acid challenge and that 
Sub-A-mPEG can degrade gliadins once released.   
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Figure 29. Sub-A-mPEG-PLGA after acid challenge can degrade gliadins. Sub-A (A) 
or Sub-A-mPEG-PLGA (B) were incubated at 37°C in acidic conditions (pH3) for 0h, 3h, 
or 24 h, and then transferred to pH 7.0. Enzyme activity was monitored at t=0 and t=1h 
using mixed gliadins as the substrate. Lane 1: MW; Lane 2, 4, 6: Sub-A or Sub-A-mPEG-
PLGA in pH 3.0 for 0, 3, 24 hr, then gliadin added and incubated for 0 hr; Lane 3, 5, 7: 
Sub-A or Sub-A-mPEG-PLGA in pH 3.0 for 0, 3, 24 hr, then gliadin added and incubated 
for 1 hr.  
 
4.3.6. Sub-A-mPEG-PLGA coating and pepsin exposure 
The effect of PLGA coating on pepsin resistance was investigated. The compounds (Sub-
A-mPEG-PLGA) were pre-incubated in low pH buffer (pH 3.0) with pepsin (final 
conc.10ug/ml), and then transferred to a buffer with a neutral pH. The Sub-A controls were 
inactive after the acid and pepsin challenge. However, Sub-A-mPEG-PLGA was active 
after the pepsin challenge (Figure 30). These results indicate that the PLGA coating had 
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protected the encapsulated Sub-A-mPEG enzyme from degradation during the pepsin 
exposure.  
 
Figure 30. mPEG-PLGA modification renders Sub-A resistant to pepsin. Enzyme 
preparations pre-incubated at pH 3.0 in the presence of pepsin (final conc. 10ug/ml) and 
tested the AAPF cleavage activity at pH 7.0, n=3. 
 
4.3.7. Detoxification of gliadin immunogenic epitope in vivo 
To experimentally explore if Sub-A-mPEG-PLGA would be able to degrade and detoxify 
gliadins during gastro-duodenal transit, an in vivo experiment was carried out. Three 
groups of 9 female mice were fasted for 18 hr, and each them received either mice chow 
alone, mice chow supplemented with Sub-A or mice chow supplemented with Sub-A-
mPEG-PLGA. The mice ingested the 1 g chow, in 1 hr. After digestion for two more hours, 
the stomach contents of the mice were harvested, gliadin peptides extracted and assessed 
for the presence of the R5 epitope, which represents a highly immunogenic gliadin peptide 
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domain, in an ELISA assay. As shown in Figure 31, gluten immunogenic epitopes were 
reduced by 31.9 % in the stomach of the mice fed with chow non-modified Sub-A. 
However, the reduction was significantly higher (p <0.01) at 60.0 % in mice fed with chow 
supplemented with Sub-A-mPEG-PLGA. This showed that the efficacy of gliadin 
degradation in vivo was doubled after enzyme modification with mPEG and encapsulation 
by PLGA. Overall, the enzymes in their current modified form are likely to efficiently 
remove epitopes from the gastrointestinal lumen, especially in the pH-neutral duodenal 
region, thereby lowering the chances for inflammatory responses as observed in celiac 
disease.  
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Figure 31. Sub-A-mPEG-PLGA is active in vivo. Three groups of mice were treated 
either with gluten-containing chow only (n=9), chow supplemented with Sub-A (n=9) or 
chow supplemented with Sub-A-mPEG-PLGA. After 3 h, mice were euthanized, stomach 
contents harvested, and the survival of the R5 epitopes was determined in an ELISA 
assay. A, Box plot showing the individual data points; B, Average +/- SEM. Data were 
analyzed with SPSS. ***p < 0.001.  
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5. DISCUSSION 
Part I  
Despite the fact that oral bacteria are present in high amounts and in a wide variety in the 
oral cavity, and are being swallowed in large numbers daily, their roles beyond the oral 
cavity are not well understood. Here we demonstrated that Rothia species can degrade 
dietary proteins, in vitro, as well as in vivo. This finding suggests that this species, and 
perhaps other oral microbes as well, may play a role in the initiation of the digestion of 
foods. 
 R. aeria is a gram positive bacterium belonging to the Rothia genus and is a natural 
colonizer, similar to R. mucilaginosa and R. dentocariosa. R. aeria exhibits a superior 
gliadin degrading activity compared to R. mucilaginosa (Zamakhchari et al., 2011). In the 
present study the gliadin-degrading enzyme produced by R. aeria was identified as being 
a member of the peptidase S8 family, like the enzyme previously isolated from R. 
mucilaginosa (Wei et al., 2016).  
 Peptidase S8 belongs to the subtilases family, a group of enzymes which were first 
isolated from Bacillus subtilis (Ottesen and Spector 1960). Since Bacillus species also 
available in the oral cavity, like Rothia species (Dewhirst et al., 2010), we compared the R. 
aeria and B. subtilis gliadin-degrading activities. R. aeria was found to have a higher 
activity than B. subtilis. More Importantly R. aeria, but not B. subtilis, exerted appreciable 
activity at acidic (pH 3.0). Since the pH in the stomach is around pH 3.0 after 1 hr of food 
ingestion (Dressman 1986), this suggests that under certain conditions, R. aeria may be 
active in the stomach. Based on the activity of R. aeria at low pH, it was chosen for the in 
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vivo gliadin digestion experiment in mice, anticipating that it could be active under gastric 
conditions. Indeed, R. aeria fed to mice supplemented to chow, showed evidence for 
gliadin-degrading activity in the stomach.  
 The amino acid sequence of the enzyme from R. aeria was 99% homologous to that 
of a subtilisin expressed by R. dentocariosa. This would suggest that R. dentocariosa could 
degrade gliadin as well. However, our preliminary investigations showed that R. 
dentocariosa is substantially less efficient in degrading gluten than either R. aeria or R. 
mucilaginosa (unpublished observations). There are several explanations for this, for 
instance that the R. dentocariosa enzyme is not expressed, or expressed at much lower 
levels. The breath of expression of subtilisins in the Rothia family and in other genera needs 
further exploration, for instance, by gliadin zymography analysis of individual species. 
The R. aeria protein identified in the gliadin degrading protein band was 
BAV86562.1. This protein was seemingly miss-annotated in the NCBI data base as a 
glycerol-3P-ABC transporter, because of its structural features lacking any of the 
characteristics of an ABC transporter. ABC transporters are characterized by two 
nucleotide-binding domains (NBD) and two transmembrane domains (TMDs), and a 
signature sequence or motif, LSGGQ which is involved in nucleotide binding (Wilkens 
2015). BAV86562.1 does not contain the LSGGQ sequence. It does contain the D-H-S 
catalytic triad with flanking regions characteristic for the subtilisin family of proteases. 
Thus, BAV86562.1 expressed by R. aeria is a peptidase S8 subtilisin and not an ABC 
transporter.  
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 Gliadin degradation is dependent on the amount of bacteria, the amount of gluten 
protein, and incubation time. With regard to the bacteria amount, we found that R. aeria 
exerted gliadin degradation in a dose dependent manner. Based on in vitro studies 
employing various ratios of bacteria and gliadins, a dose of 2.4x1010 CFU/g of chow was 
selected for the in vivo study. This dose is not unrealistic, considering that probiotic 
applications can contain as high as 1011 CFU per application (Jose et al., 2015) . 
 The time between the feeding of the chow and euthanize of the mice was 3 hr. The 
selected time span was based on a report that described the gastrointestinal transit time in 
mice assessed with 99mTc-DTPA-labeled activated charcoal. Within 3 hr the labelled 
material could be detected in the stomach and the entire small intestine (Padmanabhan et 
al., 2013). Our pilot studies showed that the incubation time required for gliadin ingestion 
was 1 hr and for gliadin degradation 2 hr. Therefore, 1 hr feeding and 2 hr digestion for a 
total of 3 hr was selected for the in vivo mice experiments.  
 The first pilot in vivo experiment revealed that after 3 hr most of the protein 
(gliadin) was present in the stomach (64%), and 36% in the small intestine, in accordance 
with the previously published gastrointestinal transit studies. The gliadin bands were 
virtually absent in the small intestine for both the control and R. aeria fed mice, while the 
gliadins were detectable in the stomach compartment.  The low amounts of gliadins found 
in the small intestines can have several explanations. First, small amounts of material 
(chyme) were recovered from the small intestines, which could have led to inaccuracies in 
protein concentration determination. Second, mice (unlike humans) degrade gliadins 
effectively in the small intestine by the combination of trypsin, chymotrypsin and brush 
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border enzymes, enzymes which are not present in the stomach. Therefore, in the 
subsequent digestion studies only the gastric contents were investigated for gliadin 
survival.  
The in vivo experiment with nine mice per group showed that R. aeria bacteria 
reduce the gliadin content in the stomach before it reaches the duodenum. The reduction 
of gliadins by 20% compared to the control was statistically significant. However, the mere 
reduction of gliadins is not sufficient because the incomplete digestion of immunogenic 
domains could lead to fragments that could more easily reach the lamina propria, and 
become harmful to the host (Rizzello et al., 2007). But, our study results demonstrate that 
in addition to reducing gliadin content, R. aeria also reduces the immunogenic epitopes of 
gliadin, and the reduction of immunogenic gliadin epitopes achieved was 32.6%. Together 
the studies indicate that Rothia aeria or its enzyme could aid in gluten digestion. Since the 
identity of the R. aeria enzyme has been revealed in this study, and theoretically can be 
cloned and expressed in high doses, such applications become within reach. 
 
Part II 
The structure-function analysis of Sub-A from B. Licheniformis revealed that it is a 
remarkably unstable enzyme. This was evident from SDS PAGE analysis of subtilisin 
dissolved in neutral or alkaline solutions, showing only bands  with molecular weight of 
<10 kDa while the band with the expected 27 kDa was absent. Sub-A degradation, could 
be prevented at low pH. The fact that acid pH prevented degradation strongly suggested 
that Sub-A undergoes autolysis. The significance of this observation is that it highlights a 
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feature of the enzyme that needs to be taken into account for therapeutic application of the 
enzyme in aqueous solutions.  
The optimal pH for the activity of subtilisin-A lies between 7 and 10, as  assessed 
with the substrate Suc-AAPF-pNA. Consequently, most of the autolysis, too, is observed 
at neutral to basic pH. Indeed, subtilisins are more stable at acid pH than at alkaline pH 
(Wong 1995). In agreement, we found that Sub-A 27 kDa band was visible at acidic pH 
but not at neutral pH (Figure 23A). At acidic pH, no activity towards AAPF is detected.  
Subsequent transfer of the enzyme to neutral pH could not rescue the activity (Figure 26). 
This is likely due to enzyme denaturation at low pH.  
Sub-A is a serine protease and can be covalently inactivated by standard serine 
protease inhibitors such as phenylmethanesulfonyl fluoride (PMSF) (Morihara and Oka 
1970). In this study Sub-A incubated with PMSF also showed an intact 27 kDa band 
evidence for the absence of autolysis. The pH and inhibitor results combined provide strong 
evidence that the instability of Sub-A at pH > 7.0 is likely due to the autolysis of the 
enzyme. 
Sub-A is reportedly active in some organic solvents. DMSO like other organic 
solvents will significantly affect the secondary structure of biomolecule including proteins. 
In this study, 50% DMSO did not affect the activity of Sub-A, which showed comparable 
activity to the enzyme dissolved in water (pH 6.0) (Figure 22).  These results point to 
autolytic activity of the enzyme, even in the presence of 50% DMSO. Activity in the 
presence of organic solvents is not unusual. For instance, trypsin, another serine protease, 
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has also been demonstrated to be active in 20 % of DMSO, even more active than in the 
absence of DMSO (Heinrich 1972). 
Other factors, such as temperature and time, also impact the enzyme stability and 
activity, the extend of which was investigated in this study. During these investigations it 
was repeatedly observed that enzyme degradation precedes the loss of activity. In other 
words, it appeared that the enzyme had undergone substantial autolysis while the activity 
was still detectable (Figure 22). Further studies are needed to investigate the reason why 
the loss of subtilisin enzyme protein band did not coincide with the loss of activity. 
 
Part III 
In general, protein-based drugs hold great promise as new therapeutic agents because of 
their high specificity. Unfortunately, they are limited by their short half-life in the organism 
to be treated. This drawback is caused by premature proteolytic degradation, rapid renal 
clearance, and instabilities of the protein itself. Instability of enzyme proteins is one of the 
major challenges for their therapeutic application. The micro-encapsulation technique is 
considered a suitable way to improve the stability by modification of the polypeptide 
features while the main biological functions, such as enzymatic activity or receptor 
recognition are maintained (Veronese 2001). Enteric coating, as by a polymer barrier, is 
one of the methods that is frequently used to protect protein drugs from disintegration in 
the gastric environment (Peter 1990). Microspheres made of albumin were initially 
suggested to be useful as drug delivery systems (Kramer 1974). More than 20 years later, 
microspheres are being utilized as sustained release vehicles, where the drugs are released 
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through the pores of the microspheres (Madhav and Kala 2011). PEGylation and 
microencapsulation are two commonly used methods which already have proven great 
potential in achieving protein drug stability. It has been demonstrated that proper PEG 
modification is necessary to achieve protein stability, e.g. preventing chymotrypsin from 
activity loss by encapsulation in PLGA microspheres (Castellanos et al., 2005).  The 
combination of these methods is applied in this work using subtilisin-A as a model of a 
gliadin degrading enzyme and mPEG and PLGA as polymers. Our results confirm that 
PEGylation and microencapsulation can protect subtilisin-A from inactivation due to 
autolysis or due to acid exposure.  
Subtilisins have a potential to be used for therapeutic application in the treatment 
of celiac diseases, due to their gluten-degradation feature. However, subtilisin-A is, like 
many other enzymes, only weakly active under acidic conditions. Subtilisin-A enzyme is 
a serine protease. It is composed of two alpha-helices, and a large beta-sheet structure. 
Also, it has an active site (catalytic triad), consists of Asp32 (D), His64 (H), and Ser221 
(S) (Wong 1995). The catalytic activity of the enzyme depends on the three dimensional 
shape of the protein, which is normally held by ionic bonds in its proper confirmation at 
neutral pH.  In the presence of high proton concentrations under acidic conditions the 
tertiary structure of the enzyme molecule is altered, leading to denaturation (PATEL 2014).  
In this study, we confirmed that subtilisin-A was active towards gliadin substrates 
at neutral pH.  However, the activity was lost at low pH, and could not be recovered after 
being transferred to neutral pH. This suggests that the active sites of subtilisin-A maybe be 
denatured, fully, or in part, in the acidic environment. In an effort to make subtilisin-A 
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therapeutically applicable in the clinic, we pharmaceutically modified the enzyme in two 
step procedure using a combination of PEGylation and PLGA microencapsulation to 
stabilize and to protect the enzyme under acidic conditions. 
The PEGylation technique is a covalent modification of polypeptide drugs with a 
synthetic poly (ethylene glycol), “PEG” polymer, such as mono-methoxylated PEG 
(mPEG). This technique was first introduced in the late 1970s, and mostly utilized for 
protein drug delivery conjugation after 1990s (Kadajji and Betageri 2011). In this study, 
we successfully modified the subtilisin enzyme with mPEG which protected the enzyme 
from autolytic activity, while retaining its ability to digest externally added substrates. 
The size of mPEG has been reported as a factor to impact the efficiency of PEG 
modification. mPEG with molecular weights 5 kDa have been found to be the most 
efficient for conjugation with enzyme proteins (Al-Azzam et al., 2005; Castellanos et al., 
2005; Rodríguez-Martínez et al., 2009).  Based on this finding, we modified the subtilisin 
enzyme with 5 kDa mPEG and achieved a high conjugation efficiency with a ~55% yield, 
which is comparable to other studies in which the PEG modification efficiency ranges 
between 50-60% (Radi et al., 2016; Rodríguez-Martínez et al., 2009). The size of the 5 kDa 
mPEG appear to be optimal for maintaining enzyme catalytic activity. Larger MW 
(>10KDa) PEG molecules tend to fold and occupy a large surface area of the protein, 
interfering with substrate binding ability (Manjula et al., 2003; Svergun et al., 2008), and, 
this is circumvented by employing the smaller molecular weight PEG for modification.  
To validate the mPEG modification of Sub-A, we investigated the extent of mPEG 
modification by fluorescamine and TNBSA assays (Al-Azzam et al., 2005). The TNBSA 
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has the advantage of recognizing the primary amines in unfolded proteins, compared to the 
fluorescamine assay that acts on folded proteins. Sub-A has 10 primary amines including 
9 Lysine (K) amino acids and one free N-terminus site (Smith et al., 1968). Our study 
shows ~8 of the 10 primary amines in Sub-A were PEGylated determined by fluorescamine 
assay and ~6 of the 10 primary amines in Sub-A were PEGylated determined by TNBS 
assay. The PEGylation rate determined by the fluorescamine assay (81.6%) was higher 
than that of TNBSA (55.4%). This is because the hidden non-PEGylated primary amine of 
the protein in folded status are falsely detected as “PEGylated”.    
While 6 out of 10 primary amines were PEGylated in Sub-A-mPEG, the activity 
was comparable with the native enzyme (Sub-A) as shown in Figure 26. ~60% PEGylation 
has been demonstrated in previously published, work which revealed no significant 
changes in secondary and tertiary structure of the enzyme protein (Rodríguez-Martínez et 
al., 2009), and still shows significant activity (Gioacchini et al., 1997). It is likely that a 
lower degree of PEGylation (e.g., at least 1/10, 2/10, 4/10) may improve enzyme activity. 
On the other hand, the lower degree of PEGylation tend to decrease the desired stability of 
the enzyme.  
In addition to the linear mPEG polymers used in this study, in the future branched 
mPEG polymers could also be used. Monfardini et al., (1995) demonstrated that drugs 
bound to branched polymer PEG chains are better than drugs modified with linear PEG 
chains  to enhance the pH and thermal stability of the drug and improve the resistance to 
proteolysis (Monfardini et al., 1995), as well as to decrease the immunogenicity of the drug 
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(Francesco et al., 1997). The activity of PEGylated Sub-A was stable at neutral pH but 
diminished under acid conditions as shown in Figure 26 and Figure 27.  
In an effort to improve the protection efficiency of PEGylated subtilisin-A under 
acid conditions, we further coated PEGylated subtilisin-A with food-grade synthetic Poly 
(lactic-co-glycolic acid), “PLGA” copolymers.  PLGA is a FDA approved polymer, the 
features such as water-insoluble, predictability of degradation, ease of fabrication, strength, 
hydrophobicity, biocompatible and pliability make PLGA a desired polymeric vehicle for 
medical applications (Crotts and Gwan Park 1995; Gombotz and Pettit 1995; Sah et al., 
1995).  
Our in vitro experiment showed that PLGA microencapsulation preserves enzyme 
activity of AAPF cleavage and gliadin hydrolysis under neutral conditions. More 
interestingly, the activity of PEGylated subtilisin-A coated with PLGA (Sub-A-mPEG-
PLGA) was dramatically protected under acid conditions as compared to the non-PLGA 
coated enzyme.  
The mechanisms of drug release from PLGA coatings have been reported, which 
include collective degradation process of bulk diffusion and erosion, surface diffusion and 
erosion (Cai et al., 2003). The degradation of PLGA depends on many factors such as 
molecular weight of the polymer, the degree of crystallinity, the glass transition 
temperature (Tg) of the polymer, and the size and shape of the matrix (Makadia and Siegel 
2011). One of the remarkable advantages of PLGA is that the PLGA polymer coating 
degrades slower at low pH than at high pH. Consequently, the enzyme release from PLGA 
encapsulations will decrease and the coated drug will be more stable and controlled at low 
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pH as a zero-order release profile (Guo et al., 2017). Likewise, the PEGylated subtilisin-A 
showed a sustained release in the acid environment so that the activity was protected until 
the drug reached a neutral environment that favors PLGA degradation and release.  
The enzyme type, load, and conjugation also impact the release rate and pattern of 
the coated enzyme (Makadia and Siegel 2011). The presence of the PEG polymer 
conjugated with the enzyme in our study may play a role in the release profiles of 
PEGylated subtilisin-A. Since there are many variables that influence the degradation 
process, the release rate and patterns are often unpredictable, especially in vivo where the 
pH conditions can fluctuate in time and in anatomical location. Further investigations are 
required on the exact mechanism of the combination of conjugation and encapsulation to 
enhance protection of subtilisin enzymes against the acidic environment and promote their 
release and activity at neutral pH.  
The animal experiment confirmed the in vitro finding, where the encapsulated 
enzyme was better protected than subtilisin-A and twice as efficient in degrading gliadins. 
Activity was measured in the stomach contents. It can readably be envisioned that activities 
would even be higher in the neutral duodenal environment, where PLGA dissolution and 
PEGylated enzyme release would be favored.  
Overall, the combination of mPEG and PLGA coating of subtilisins provides a 
novel strategy to deliver acid-resistant gluten-degrading enzymes to the gastrointestinal 
canal for the detoxification of gluten immunogenic epitopes in patients with celiac disease 
or other gluten related disorders. To our knowledge, this is the first study to demonstrate a 
synergistic effect of PEGylation and PLGA encapsulation for enteric coating to preserve 
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the activity as well as stability of subtilisins. The combination of PEGylation and 
microencapsulation could be used to modify other gluten-degrading enzymes, e.g. prolyl 
endopeptidases, to improve their stability and preserve activity, and may be considered a 
promising modality for future therapeutic avenues in enzyme therapeutics. 
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6. SUMMARY 
Recent work in oral medicine and oral biology showed a link between salivary secretions 
and oral microorganisms with gastro-intestinal physiology. An example of such a 
connection is the recent discovery of unusual enzymes derived from oral microorganisms 
which are highly effective in the proteolytic degradation of gliadins. This is of importance 
since gliadins represent the major culprit in the etiology of celiac disease. The enzymes 
responsible for gluten fragmentation are derived from several bacterial species found in the 
oral cavity. A new discovery made in our laboratory is the identification of Rothia species 
in the oral microbiome exhibiting characteristics uniquely relevant as a candidate for the 
development for clinical applications in CD patients. 
 The subtilisin enzyme identified and described here from Rothia aeria showed 
degradation of gliadins and gliadin immunogenic epitopes. This activity was investigated 
in vitro and in animal experiments using mice chow mixed with Rothia aeria strains. The 
in vitro data of subtilisin-A from Bacillus licheniformis showed high gliadin degradation 
at neutral pH. The Bacillus-derived enzyme was less affective at low pH and showed signs 
of autolysis at neutral to high pH. Optimal protection of the enzyme was achieved by a 
combination of PEGylation and PLGA microencapsulation. This treatment clearly helped 
to maintain the stability of the Sub-A enzyme in acidic conditions and to prevent its 
proteolysis by pepsin. In vivo results in mice showed 60% reduction of gliadin 
immunogenic epitopes, which is encouraging with respect to novel celiac disease treatment 
modalities. 
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